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INTRODUCTION 
 
Many functions of the human body vary considerably in a day. These variations 
cause changes both in disease state and in plasma drug concentrations. Human 
circadian rhythm is based on sleep-activity cycle, is influenced by our genetic 
makeup and hence, affects the body’s functions day and night (24-hour period) 48. 
The dependence of bodily functions in certain disease states on circadian rhythm is 
well known. A number of hormones are released by the brain in the morning, while 
others are released during sleep. Blood pressure and heart rate are highest during 
the hours of 6.00 a.m. to 12.00 noon 49. 
 
Diseases, such as hypertension, asthma, peptic ulcer, arthritis, etc, follow the body's 
circadian rhythm 50. For example, osteoarthritis worsens during the day and is most 
bothersome in the evenings but for people with rheumatoid arthritis, the pain 
usually peaks in the morning and decreases as the day progresses. Cardiovascular 
diseases such as hypertension and angina, and chest pain, also follow a definite 
circadian rhythm. Epidemiologic studies have documented the heightened 
morning-time risk of angina, myocardial infarction, and stroke 51.  
The goal in drug delivery research is to develop formulations to meet therapeutic 
needs relating to particular pathological conditions. Research in the 
chronopharmacological field has demonstrated the importance of biological 
rhythms in drug therapy, and this has brought a new approach to the development 
of drug delivery systems. Optimal clinical outcomes cannot be achieved if drug 
plasma concentrations are constant. If symptoms of a disease display circadian 
variation, drug release should also vary with time. Utilization of different 
technologies in the development of time-controlled, pulsed, triggered and 
programmed drug delivery devices has intensified in recent years.  
Another issue that has emerged from circadian variation of physiological function 
is that drug pharmacokinetics can be time dependent (i.e., chronopharmacokinetics) 
52. Therefore, variation in disease state and drug plasma concentration need to be 
taken into consideration in the development of drug delivery systems intended for 
the treatment of diseases with adequate dose at the appropriate time. The term, 
‘Chronopharmaceutic drug delivery system’, is used to describe a kind of drug 
formulation which can cause circadian variation in drug plasma levels 53,54.55. 
CHRONOTHERAPEUTICS 
The term "chrono" basically refers to the observation that every metabolic event 
undergoes rhythmic changes in time. Researchers have concluded that all living 
organisms are composites of rhythms with varying frequencies that may range from 
seconds to seasons. Perhaps the best known and studied chronobiologic frequency 
is the circadian rhythm which approximates the earth's 24-hour rotation around the 
sun 56. Researchers have recently concluded that both disease states and drug 
therapy are affected by a multitude of rhythmic changes that occur within the 
human body 50.  
Chronotherapeutics refers to a treatment method in which in vivo drug availability 
is timed to match rhythms of disease in order to optimize therapeutic outcomes and 
minimize side effects. It is based on the observation that there is an interdependent 
relationship between the peak-to-trough rhythmic activity in disease symptoms and 
risk factors, pharmacologic sensitivity, and pharmacokinetics of many drugs 58. As 
more continues to be learned about chronobiology and chronotherapeutics, it is 
becoming increasingly more evident that the specific time that patients take their 
medication may be even more significant than was recognized in the past. The 
tradition of prescribing medication at evenly spaced time intervals throughout the 
day, in an attempt to maintain constant drug levelsthroughout a 24-hour period, 
may be changing as researchers' report that some medications may work better if 
their administration is coordinated with day-night patterns and biological 
rhythms.48. 
Diseases and chronotherapeutics 
Up to now, design of drug delivery systems has been governed by the homeostatic 
theory 59. This theory is based on the assumption of biological functions that 
display constancy over time. However, chronobiological studies have established 
circadian rhythm for almost all body functions, e.g., heart rate, blood pressure, 
body temperature, plasma concentration of various hormones, gastric pH and renal 
function 60. It has become apparent that rhythmic processes are indispensable for 
the treatment of human diseases. Just as physiological functions vary over time, 
pathological states of disease have circadian rhythms. Epidemiological studies have 
documented the elevated risk of disease symptoms during the 24-hour cycle (see 
Fig.) 61.  
 
Figure 1: Diseases ln own to display circadian rhythm 
The potential benefits of chronotherapeutics have been demonstrated in the 
management of a number of diseases. In particular there is a great deal of interest 
in how chronotherapy can particularly benefit patients suffering from allergic 
rhinitis, rheumatoid arthritis and related disorders, asthma, cancer, cardiovascular 
diseases, and peptic ulcer disease 50. Patients with allergic rhinitis often report that 
they suffer their worst symptoms when they wake up in the morning. Patients may 
obtain better results in controlling this morning discomfort if they were to take a 
long-acting antihistamine at night rather than taking the medication in the morning 
as is frequently recommended 48. 
Anti-inflammatory therapy 
In the case of individuals who suffer from rheumatoid arthritis and related painful 
joint disorders, the non-steroidal anti-inflammatory agents (NSAIDs) such as 
ibuprofen may be more effective at relieving pain, if the drug is administered at 
least 4 to 6 hours before the pain reaches its peak. It will be more helpful if arthritis 
patients take the NSAIDs before bed time if they experience a particularly high 
level of discomfort in the morning . 61. 
Anti-asthma therapy 
It has been estimated that symptoms of asthma occur 50 to 100 times more often at 
night than during the day 62. Many circadian-dependent factors appear to 
contribute to the worsening of nocturnal asthmatic symptoms. For example, 
cortisol (an anti-inflammatory substance) levels were highest at the time of 
awakening and lowest in the middle of the night, and histamine (a mediator of 
bronchoconstriction) concentrations peaked at a level that coincided with the 
greatest degree of bronchoconstriction at 4:00 am 50. A research finding also 
reveals that theophylline absorption is slower at night 47. The enhanced 
understanding of the chronobiological impact upon the pathology of asthma, and 
the pharmacology and pharmacokinetics of the drugs used in its management, have 
led to new approaches to disease management and enhanced patient care. 
Chemotherapy 
Antineoplastic drugs cause cytotoxic effects on healthy and diseased tissues. As 
would be expected, the biological rhythms of both healthy and tumor cells may 
influence the susceptibility of normal and malignant cells to these agents 62. It has 
been demonstrated that "susceptibility rhythms" to drugs may differ between 
healthy tissue and cancerous tissue. Therefore, the "correct" timing of drug 
treatment may reduce host toxicity, increase maximum drug tolerance, and 
ultimately result in better tumor management. The pharmacologic and 
pharmacokinetic properties of the drug, rhythmic changes in DNA and RNA 
synthesis, RNA translational activity and mitotic activity may influence tumor cell 
susceptibility 50. It appears that the timing of drug administration in the treatment 
of cancer can have a significant impact upon treatment success. 
Cardiovascular therapy 
The differences in patterns of illness between day and night for cardiovascular 
disorders such as hypertension, angina, heart attack, sudden cardiac death and 
stroke have been documented 48. Medications have been formulated, and dosing 
schedules established, in an attempt to provide appropriate concentration of a drug 
in the target area of the body when the drug is most needed48. For example, it has 
often been found that the blood pressure of a hypertensive patient increases rapidly 
in the morning after awakening, typically peaks in the middle to late time of the 
day, decreases in the evening, and is lowest while the patient sleeps at night 48. It 
may also be important to recognize that the risk of heart attack appears to be 
greatest during the early morning hours after awakening. Currently, there are 
antihypertensive products in the market that are chronotherapeutic medications 
with novel drug delivery systems, releasing drug during the vulnerable period of 6 
am to noon upon administration of medications at 10 pm. Some of these are listed 
in Table 1. 
Table 1: Some chronotherapeutic antihypertensive products 
Product Generic name Manufacturer 
InnoPran XL Propranolol GlaxoSmithKline USA 
Cardizem LA Diltiazem Biovail Corporation Mississauga, ONCanada 
Verelan PM Verapamil Schwars Pharma Monheim, Germany 
Covera HS Verapamil G. D. Searle (a division of Pfizer),NY, USA 
 
Anti-ulcer therapy 
It is well established that patients with peptic ulcer disease often experience the 
greatest degree of pain near the time that they go to bed, as the rate of stomach acid 
secretion is highest at night 48. The timing of administration of ulcer medications 
has a significant impact on their therapeutic effect. 
CHRONOPHARMACOKINETICS 
Chronopharmacokinetics entails the study of temporal changes in drug absorption, 
distribution, metabolism and excretion 63. Pharmacokinetic parameters, which are 
conventionally considered to be constant in time, are influenced by various 
physiological functions displaying circadian rhythm. Circadian changes in gastric 
acid secretion, gastrointestinal motility, gastrointestinal blood flow, drug protein 
binding, liver enzyme activity, renal blood flow and urinary pH may play a role in 
time-dependent variation of drug plasma concentration 63-65. Numerous 
chronopharmacokinetic studies have been conducted over the last 20 years 63-66. 
The results of these studies demonstrate that time of administration affects drug 
kinetics. Studies in man have been reported, particularly in relation to 
cardiovascular active drugs, non-steroidal anti-inflammatory drugs (NSAIDs), local 
anaesthetics, anticancer drugs, psychotropic drugs, antibiotics and anti-asthmatic 
drugs 64. Most of the drugs seem to have a higher rate or extent of bioavailability 
when they are taken in the morning than when they are taken in the evening. 
Anti-hypertensive drugs 
For example, with cardiovascular drugs such as nifedipine, oral nitrates and 
propranolol, plasma peak concentration is twice as high and time to reach peak 
concentration is shorter after morning dosing compared with evening dosing 63. 
Such a variation was not detected when sustained release dosage forms of 
nifedipine and isosorbide mononitrate were used. The underlying mechanisms of 
their chronopharmacokinetic pattern involve a faster gastric emptying time and a 
greater gastrointestinal perfusion in the morning. Shiga et al documented that 
atenolol, in contrast to propranolol, is not absorbed more rapidly after morning 
administration compared with post-evening administration 66. This confirms that 
the absorption rate of a lipophilic, but not hydrophilic, drugs is faster after morning 
dosing 67. 
Anti-inflammatory drugs 
Studies on NSAIDs, e.g., indomethacin and ketoprofen, have also shown that these 
drugs have a greater rate and/or extent of bioavailability when they are given in the 
morning than when they are given in the evening. Markedly higher ketoprofen 
plasma peaks were observed after administration at 07:00 than after administration 
at other times 68. Earlier and higher peak concentrations were obtained when 
indomethacin was given at 07:00 or 11:00 than at other times of the day or night 69. 
Better morning absorption has also been observed with controlled release 
indomethacin and ketoprofen formulations 70,71. The clinical relevance of such 
variations is that high plasma concentrations correlate with high incidence of 
adverse effects. It has been suggested that morning absorption for these drugs is 
better than night-time absorption. Greater blood flow of the gastrointestinal tract in 
the morning than in the evening may explain this phenomenon. Circadian changes 
in renal function, plasma protein binding or hepatic blood flow could also explain 
temporal variation in drug plasma levels. Many variables are known to influence 
pharmacokinetics. In chronopharmacokinetic studies, it is important to strictly 
control the time of drug administration. When symptoms of the disease are 
circadian-dependent or drug used has a narrow therapeutic range, a 
chronophannacokinetic study should be performed. The studies should be 
conducted under controlled conditions, including fasting time, composition of 
meals and posture. 
CHRONOTHERAPEUTIC DRUG DELIVERY SYSTEMS 
Controlled release formulations can be divided into subgroups of rate-controlled 
release, delayed-release and pulsed-release formulations. Delayed-release 
formulations include time-controlled release and sitespecific dosage forms 73-75. 
When constant drug plasma levels need to be avoided, as in chronotherapy, time-
controlled or pulsed-release formulations are preferable, especially in the treatment 
of early morning symptoms. By timing drug administration, plasma peak is 
obtained at an optimal time and the number of doses per day can be reduced. 
Saturable first-pass metabolism and tolerance development can also be avoided 75. 
Various technologies to develop timecontrolled peroral drug delivery systems have 
been extensively studied in recent decades. Some of these systems are discussed in 
the following subsections. 
Enteric-coated systems 
Enteric coatings have traditionally been used to prevent the release of a drug in the 
stomach (see Fig 2). Enteric coatings are pHsensitive and drug is released when pH 
is raised above 5 in the intestinal fluid. These formulations can be utilised in time-
controlled drug administration when a lag time is needed. Because of the 
unpredictability of gastric residence, such systems cannot be the first choice when a 
time-controlled release is required. In the treatment of nocturnal asthma, a 
salbutamol formulation containing a barrier coating which is dissolved in intestinal 
pH level above about 6, has been successfully used 76. The system contains a core 
which is film coated with two polymers, first with HPMC and then with a gastro-
resistant polymer (Eudragit® L30D). In this system the duration of the lag phase in 
absorption can be controlled by the thickness of the HPMC layer.  
 
Figure 2: Schematic representtion of enteric coated system 
Layered systems 
These are one or two impermeable or semipermeable polymeric coatings (films or 
compressed) applied on both sides of the core 77. To allow biphasic drug release, a 
three layer tablet system was developed 72. The two layers both contain a drug 
dose. The outer drug layer contains the immediately available dose of drug. An 
intermediate layer, made of swellable polymers, separates the drug layers. A film 
of an impermeable polymer coats the layer containing the other dose of drug. The 
first layer may also incorporate a drug-free hydrophilic polymer barrier providing 
delayed (5 h) drug absorption. Conte et al has also studied a multi-layer tablet 
system (Geomatrix®). It consists of a hydrophilic matrix core containing the drug 
dose. This kind of three layer device has been used in the treatment of Parkinsonian 
patients using L--dopa/benserazide 78. Night-time problems and early-morning 
symptoms of Parkinsonism can be avoided by using a dual-release Geomatrix@ 
formulation, which allows daily doses of drug to be reduced and leads to extent of 
bioavailability 40 % greater than when a traditional controlled release formulation 
is employed. 
Time-controlled explosion systems (TES) 
These have been developed for both single and multiple unit dosage forms 79, 80 . In 
both cases, the core contains the drug, an inert osmotic agent and suitable 
disintegrants. Individual units can be coated with a protective layer and then with a 
semipermeable layer, which is the rate controlling membrane for the influx of 
water into the osmotic core. As water reaches the core, osmotic pressure is built up. 
The core ultimately explodes, with immediate release of the drug. The explosion of 
the formulation  also be achieved through the use of swelling agents. Lag time is 
controllable by varying the thickness of the outer polymer coating. 
Sigmoidal release systems (SRS) 
For the pellet-type multiple unit preparations, SRS containing an osmotically active 
organic acid have been coated with insoluble polymer to achieve different lag-
times 81-83. By aplying different coating thicknesses, lag times in vivo of up to 5 
hours can be achieved. Release rates from SRS, beyond the lag time, has been 
found to be independent of coating thickness. 
  
Press-coated systems 
Delayed-release and intermittent-release formulations can be achieved by press-- 
coating. Press-coating, also known as compression coating, is relatively simple and 
cheap, and may involve direct compression of both the core and the coat, obviating 
the need for a separate coating process and the use of coating solutions. Materials 
such as hydrophilic cellulose derivatives can be used and compression is easy on a 
laboratory scale. On the other hand, for large-scale manufacture, special equipment 
is needed. The major drawbacks of the technique are that relatively large amounts 
of coating materials are needed and it is difficult to position the cores correctly for 
the coating process 84.  
 Core tablet 
 
 
 Coated polymer 
  
 
         Figure 3: Schematic representation of a press coated system 
I 
In recent years, various controlled release, especially time-controlled release, drug 
delivery systems based on compression coating technology have been studied. 
Most of such formulations release drug after a lag phase, followed by a rapid 
dissolution of the core. Conte et al have developed a presscoated device in which 
the inner core contains the drug and the outer coat is made of different types of 
polymers. The outer barrier, which controls drug release, can be either swellable or 
erodible. Lag times can be varied by changing the barrier formulation or the 
coating thickness 5,7. Matsuo et al have developed a diltiazem hydrochloride 
formulation intended for use in the treatment of time-related symptoms of 
ischaemic heart disease and hypertension 85. The tablet consists of a core, which 
contains the drug, and a coat formed by compressing hydroxyethylcellulose. 
Diltiazem is rapidly released after a delay of several hours. Marvola et al have 
developed a press-coated tablet formulation in which most of the total amount of 
drug is in the tablet core 86. Hydrophilic polymers such as hydroxypropyl 
methylcellulose and sodium alginate have been used in the coat to control drug 
release as illustrated in Fig. 3. The extent of bioavailability of furosemide, 
ibuprofen and salbutamol sulphate from the system developed has been found to be 
satisfactory 92-95. 
Other systems 
Elementary osmotic pumps can be useful for delivering drugs based on 
chronotherapeutic requirements. One type of elementary osmotic pump can deliver 
salbutamol, initially at a constant delivery rate, then as a final pulse dose 96. Such a 
system could deliver a dose during a nocturnal asthma attack. The first 
chronotherapeutic system for the treatment of hypertension and angina pectoris, a 
controlled onset extended-release (COER-24) verapamil formulation, was 
developed and registered in USA 97,98. This formulation was tailored to the 
circadian rhythm of blood pressure and heart rate to better cover early morning 
symptoms of cardiovascular diseases. COER-24 is an osmotically controlled single 
unit system. Around the device, which consists of a drug layer and a push layer, are 
two membranes. The first is a semi-permeable insoluble membrane while the 
second is a release delaying hydrophilic polymer coat. Gastrointestinal fluid 
penetrates the semipermeable membrane, and as it enters the drug layer and push 
layer via the hydrated coat (within 4 to 5 hours), the push layer expands, pressing 
against the drug layer and causing drug release at a constant rate for 18 hours. If 
taken at bedtime, the system provides optimal drug concentration when the patient 
wakes up and during day time. 
Pulsinocapo is a delivery system which releases drug contents at a predetermined 
time or at a specific site within the gastrointestinal tract 99. Each capsule is 
composed of a water insoluble body and a water soluble cap, and also contains the 
drug dose which is sealed with a hydrogel plug. At a predetermined time after 
ingestion, the swollen plug is ejected from the capsule and the drug is then released 
into the small intestine or colon. The dimension of the plug and its position in the 
capsule can be varied and the system delivers drug at exactly the programmed time, 
1 to 10 hours after drug administration, to various regions of the gut. 
 
  
LITERATURE REVIEW 
 
V. S. Chopra et al, (2010)1 Studied applicability of chronotropic or pulsatile drug 
delivery systems to release the drug at desired time as per the pathophysiological 
need of disease, resulting in improved patient therapeutic efficacy and 
complianceine. Chronotropic drug delivery systems are promising in treatment of 
asthma, peptic-ulcer, cardiovascular diseases, arthritis, attention-deficit syndrome 
in children and hypercholestemia etc.  
 
Andrea Gazzaniga, Alessandra Maroni and Maria Edvige Sangalli et al, 
(2009)5 Developed pulsatile-release dosage forms to elicit programmable lag 
phases followed by a prompt or rate-controlled liberation of drugs for 
accomplishing chronotherapeutic goals, particularly in the case of widespread 
chronic pathologies with prevailing night or early-morning symptoms, such as 
bronchial asthma and cardiovascular disease. Delayed liberation of drugs has been 
attained through a range of formulation approaches, namely reservoir, capsular and 
osmotic release platforms.  
 
Dhruvita K. Pate et al, (2011) Studied Purpose of Pulsatile drug delivery is to 
release drugs on a programmed pattern at appropriate time and/or at appropriate 
site of action. Pulsatile drug delivery systems administered via the oral route could 
be divided into two types, the time controlled delivery systems and the site-specific 
delivery systems. The simplest pulsatile formulation is a two layer press coated 
tablet consisted of polymers with different dissolution rates. Homogeneity of the 
coated barrier is mandatory in order to assure the predictability of the lag time.  
 
B.U Janugade et al, (2009)2 Formulated montelukast sodium compression/press-
coated pulsatile drug delivery system by using direct compression and wet 
granulation methods to achieve the predetermined lag time. Different compositions 
of hydrophobic polymer ethylcellulose and hydrophilic polymer low-substituted 
hydroxypropylcellulose were mixed to formulate the whole layer of the outer shell 
of press coated tablets.  They conclude that lag time decreases with increasing 
concentration of low substituted hydroxypropylcellulose and wet granulation 
method gives less lag time. 
 
Parag A. Kulkarni et al, (2010)3 Studied applicability of press coated tablet with 
optimal lag time to simulate the dosing time of drug administration according to the 
pathophysiological needs. They formulated Diltiazem hydrochloride, as core and 
different compositions of klucel HF, klucel HXF, Eudragit RSPO were mixed to 
formulate the outer shell. They conclude that Diltiazem hydrochloride, released 
maximum drug 6 to 8 hours after an evening dose taken approximately 10:00 pm.  
 
Shan-Yang Lin, Mei-Jane Li, and Kung-Hsu Lin et al, (2004)4 Formulated the 
compression/dry-coated tablet with optimal lag time to simulate the dosing time of 
drug administration according to the physiological needs. Different compositions 
of ethylcellulose powder with a coarse particle and several fine particles 
respectively were mixed to formulate the whole layer of the outer shell of dry- 
coated tablets. They conclude that sodium diclofenac released from all the dry-
coated tablets exhibited an initial lag period, followed by a stage of rapid drug 
release. 
 
N. Kanaka Durga Devi et al, (2010)6 Developed and evaluated press coated tablet 
of Montelukast sodium in order to overcome disadvantages like first pass 
metabolism, peak and valley absorptions at different absorption sites and drug 
instability problems. Besides that, to treat Nocturnal asthma (NA), diseases which 
show dependency on chronopharmacology. They conclude that Montelukast 
sodium based on press coating technique has worthy effects in treating NA as well 
as to curtail extensive first pass metabolism of the drug.  
 
Mayur M. Patel, Santnu L. Patel, Manish N. Bhadani, et al, (2009)7 Formulated 
pH-dependent mesalamine Pulsatile drug delivery system. It is designed such that 
the innermost part consists of a core tablet of mesalamine which is then 
compression coated with a pH-independent hydrophilic polymer 
(Hydropropylmethyl cellulose). This is then coated with a pH-dependent 
methacrylic acid copolymer (Eudragit® S100). The concentration (coating level) of 
Eudragit® S100 was optimized to provide an enteric coat that allows the tablet to 
pass intact through the stomach and is targeted to the colon. The coating thickness 
and grades of HPMC were optimized to set a desired lag time in the intestine. From 
the in vitro evaluation it can revealed that the developed CDDS can exhibit site-
specific drug targeting to the colon. 
 
Sumit Patil et al, (2011)9 Formulated aceclofenac press-coated pulsatile drug 
delivery system for treatment of early morning stiffness and symptomatic relief 
from pain in patients with rheumatoid arthritis. The formulation involved press 
coating of a rupturable coat around a rapidly disintegrating core tablet of 
aceclofenac, Different compositions of glyceryl behenate, sodium chloride were 
mixed to formulate the coating layer of the outer shell, to investigate the influence 
of coating material on lag time.  They conclude that Glyceryl behenate had a 
significant influence on lag time, while sodium chloride helped in the rupture of the 
coat by acting as a channelling agent. After the coat was ruptured, the core tablet 
showed a rapid release of aceclofenac. 
 
B.G. Prajapati, G.N. Patei, H.K. Solanki et al, (2010)10 Formulated Propranolol 
hydrochloride  compression coated tablet using 32 full factorial Design, to evaluate 
statical influence different concentration of hydroxy propyl methyl cellulose K4M 
and ethyl cellulose on lag time to simulate the dosing time of drug administration 
according to the physiological needs. They conclude that formulation F3 exhibited 
best initial lag period, followed by rapid release of drug. 
 
J Sajan, TA Cinu, AJ Chacko, J Litty and T Jaseeda et al, (2009)11 Developed 
pulsatile-release dosage forms to elicit programmable lag phases followed by a 
prompt or rate-controlled liberation of drugs for accomplishing chronotherapeutic 
goals, particularly in the case of widespread chronic pathologies with prevailing 
night or early-morning symptoms, such as bronchial asthma and cardiovascular 
disease. Delayed liberation of drugs has been attained through a range of 
formulation approaches, namely reservoir, capsular and osmotic release platforms.  
 Ashish Babulal Rane et al, (2009) Formulated pulsatile drug delivery of 
ketoprofen using hydrophilic and hydrophobic polymer for accomplishing 
chronotherapeutic needs of rheumatoid arthritis patient. Different weight ratio of 
hydrophobic and hydrophilic polymer where mixed to formulate outer coating shell 
to exhibited an initial lag period, followed by a stage of rapid drug release. 
 
Richard J. Martin, MD, Monica Kraft, et al., (1995)12 investigated in 
Chronobiology and Chronotherapy in Respiratory medicine. It was found that, 
Chronotherapeutic delivery of theophylline, once daily in the evening between 6 
p.m & 7 p.m controls Asthma nocturnal symptoms and early morning 
bronchoconstriction. This regimen has been found to be clinically superior to 
conventional twice-daily dosing. 
 
Eiji Fukui*, Katsuji Uemura, et al., (2000)13 Studied on applicability of press-
coated tablets using hydroxypropylcellulose (HPC) in the outer shell for timed-
release preparations. It contains diltiazem hydrochloride (DIL) in the core tablet 
and coated with hydroxypropylcellulose (HPC) as the outer shell, was examined 
for applicability as timed-release tablets with a predetermined lag time and 
subsequent rapid drug release phase. Two different kinds of timed-release press-
coated tablets that showed lag times of 3 and 6 h in the in vitro test (denoted 
PCTL3 and PCTL6 respectively) were administered to beagle dogs. The lag times 
showed a good agreement between the in vivo and in vitro tests in PCTL3. 
However, the in vivo lag times were about 4 h in PCTL6 and were much shorter 
than the in vitro lag time. 
Michael H. Smolensky, Nicholas A. Peppas et al., (2007)14 Investigated on 
Chronobiology, drug-delivery and chronotherapeutics. chronotherapeutics is the 
delivery of medications in the right concentration to the right targeted tissues at the 
right time to meet biological rhythm-determined needs. Many chronic and acute 
medical conditions exhibit prominent circadian patterns of symptom manifestation 
and severity. Among the many examples are allergic rhinitis, bronchial asthma, and 
peptic ulcer disease; all tend to worsen overnight. The risk of many cardiovascular 
events, like angina pectoris, myocardial infarction, and thrombotic and 
hemorrhagic stroke, is greatest in the morning. The content of these articles clearly 
makes apparent many potential new applications of existing drug-delivery systems 
and devices, and it serves also as the basis for future developments. 
 
Sarasija Suresh, H.N. Shivakumar, et al., (2006)15 Studied on design and 
evaluation of controlled onset extended release multiparticulate systems for 
chronotherapeutic delivery of Ketoprofen. It consists of drug-loaded cellulose 
acetate cores encapsulated with in Eudragit S-100 microcapsules was designed for 
chronotherapeutic delivery of ketoprofen. Drug-loaded cellulose acetate cores were 
prepared by emulsion solvent evaporation technique in an oily phase at different 
drug: polymer ratios (1:1, 2:1 and 4:1).these cores were successfully 
microencapsulated with Eudragit S-100 following the same technique at the core: 
coat ratio of 1:5. SEM revealed that the cellulose acetate cores were discrete, 
uniform & spherical. The aim was to minimize drug release in the upper part of the 
GI tract and target the drug to the colon. 
 
Mukai B., Utoguchi N et al., (2002)16 Prepared and evaluated the press-coated 
Aminophylline tablet using crystalline cellulose and PEG in the outer shell for 
timed-release dosage forms.  The core tablet is prepared by direct compression 
method using rotary tablet punching machine. Press coating of core tablets using 
different ratios of crystalline cellulose and PEG. Tablets are evaluated for In vitro 
dissolution test showed a lag time of 6 hours. 
 
Martti Marvola et al.,( 2001)17 Studied the development and biopharmaceutical 
evaluation of press-coated tablets with the intention of administering formulation in 
the evening at 22:00, which provides treatment for diseases in which symptoms are 
experienced in the early morning hours i.e. chronopharmacotherapy. The focus is 
to optimally deliver the drug in higher amounts in early morning hours (i.e. at time 
of greatest need) and lower amounts at night (i.e. when the need of drug is less). 
 
Michael Prisant .L et al. (2001)18 Reported on Biologic rhythms are implicated in 
cardiovascular events. Failure to recognize the circadian decline in blood pressure 
may result in iatrogenic chronopathological events, including anterior ischemic 
optic neuropathy and cerebrovascular accidents. Novel drug delivery systems have 
the potential to provide antihypertensive medication at the time when the need is 
greatest. For the treatment of hypertension, this idea has the potential for a 
therapeutic paradigm shift Chronotherapeutics is the purposeful alteration of drug 
level to match rhythms to optimize therapeutic outcomes and minimize size effects 
for the treatment of hypertension. 
 
Ramon C. Hermida, Diana E. Ayala, et al., (2007)26, studied on Chronotherapy 
of hypertension: valsartan administration at bedtime, as opposed to upon wakening, 
results in an improved diurnal/nocturnal BP ratio, increased percentage of 
controlled patients, and significant reduction in urinary albumin excretion  in 
hypertensive patients. Chronotherapy provides a new option to optimize BP control 
and to reduce the risk of cardiovascular disease (myocardial infarction and stroke) 
and of end-organ injury of the blood vessels and tissue of the heart, brain, kidney, 
eye, and other organs. 
Qureshi.J, Mohd, Sanjula Baboota, et al.,( 2006)27, investigated on Pulsatile drug 
delivery system having a peculiar mechanism of delivering the drug rapidly & 
completely after a “lag time”. i.e., a period of “no drug release” though most 
delivery systems are designed for constant drug release over a prolonged period of 
time, constant blood levels of a drug may not always desirable. Pulsatile systems 
are designed in a manner that the drug is available at the site of action at the right 
time in the right amount. 
D. Searle. LLC, et al.,( 2006)28, Covera-HS has a unique controlledonset 
extended-release (COER) delivery system, which is designed for bedtime dosing, 
results in a maximum plasma concentration (Cmax) of verapamil in the morning 
hours. Covera-HS was evaluated in two placebo-controlled, parallel design, 
doubleblind studies of 382 patients with mild to moderate hypertension. In a 
clinical trial, 287 patients were randomized to placebo, 120 mg, 180 mg, 360 mg, 
or 540 mg and treated for 8 weeks (the two higher doses were titrated from low 
doses and maintained for 6 and 4 weeks, respectively). Covera-HS or placebo was 
given once daily at 10 pm and blood pressure changes were measured with 36-hour 
ambulatory blood pressure monitoring (ABPM). The results of these studies 
demonstrate that Covera-HS, at 180–540 mg, is a consistently and significantly 
more effective antihypertensive agent than placebo in reducing ambulatory blood 
pressures.  
DRUG PROFILE 
Carvedilol: 41 
Description: It is a non – selective beta blocker; it blocks β-1 and β-2 adrenergic 
receptors as well as the α-1 adrenergic receptors. It is a white or almost white, 
crystalline powder.  
Chemical Name: (2RS)-1-(9 H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)  
                              ethyl] amino] propan-2-ol 
Chemical Structure: 
 
Molecular Formula : C24H26N2O4 
Molecular Weight : 406.5 g/mole 
Melting point      : 114 - 1150C. 
Solubility   : It is easily soluble in dimethyl sulfoxide (DMSO), 
also easily soluble in methanol and methelene 
chloride, isopropranolol, ethyl ether and ethanol 
can partially dissolve. Practically insoluble in 
water. 
Dose : 25mg twice a day in the treatment of congestive 
heart failure. 
 
Elimination half life         : 6 - 8 hours 
Bioavailability                  :   25 - 35%  
PHRMACOKINETICS: 42. 
Absorption 
i.) Non-genetic 
a. Food: decreases rate (not extent) of absorption 
b. Age : 50% increase in bioavailability in elderly (increased plasma 
concentrations) 
c. Liver disease: oral bioavailability significantly increased 
d. Concomitant medications/substances: p-glycoprotein inhibitors 
ii.) Genetic 
a. Genetic variation in p-glycoprotein gene   
Distribution 
i.) Non-genetic 
a. Liver disease: 4-fold increase in volume of distribution 
b. Altered serum protein (>95% protein bound, primarily to albumin) 
c. Concomitant medications/substances: p-glycoprotein inhibitors or      
activators 
ii.) Genetic 
 a. Genetic variation in p-glycoprotein gene 
Metabolism 
 I) Non-genetic 
a. Congestive heart failure (CHF): 30-40% higher plasma concentrations 
b. Liver impairment 
i. 4- to 7-fold higher concentrations in cirrhotic liver disease 
ii. Contraindicated in severe hepatic impairment 
c. Concomitant medications/substances: CYP2C9, CYP2D6, CYP3A4, 
CYP2C19, CYP1A2, CYP2E1inducers or inhibitors 
II) Genetic 
a. Genetic variation in drug metabolizing enzyme gene(s): CYP2C9, 
CYP2D6, CYP3A4, CYP2C19, CYP1A2, CYP2E1 
 
Excretion 
i.) Non-genetic 
a .Renal impairment: increased plasma concentrations 
b .Renal impairment + hypertension: markedly increased plasma 
concentrations 
c.  50% shorter elimination half-life in paediatrics (ages 6 weeks – 19 years) 
with CHF 
d.  Age: Elimination half-life increases with age in paediatrics 
ii.) Genetic 
a. No clear genetic factors affecting excretion. 
PHRMACODYNAMICS: 
Receptors 
    i.) Non-genetic 
 a. Concomitant medications: alpha- or beta-adrenergic receptor 
agonists/antagonists (may block or enhance therapeutic effects of carvedilol) 
   ii.) Genetic 
 a.  Genetic variation in beta-1 adrenergic receptor gene 
 b.  Genetic variation in alpha-1 adrenergic receptor gene 
 c.  Genetic variation in Gs protein alpha subunit gene 
Transporters 
   i.) Non-genetic 
           Concomitant medications/substances: p-glycoprotein inhibitors or activators. 
   ii.) Genetic 
           Genetic variation in p-glycoprotein gene. 
SIDE EFFECTS AND PRECAUTIONS: 
Dizziness, Edema (fluid accumulation), decreased heart rate, diarrhea, postural 
hypotension, irregular heart rhythm, abnormalities of vision. Carvedilol should be 
used cautiously in patients who use diuretics or who are elderly or have cirrhosis, 
asthma, peripheral vascular disease, hyperthyroidism, variant angina and kidney 
disease. 
CONTRAINDICATIONS: It is contraindicated during pregnancy. 
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2) Ethyl cellulose coatings are used to modify the release of a drug, to mask an 
unpleasant taste, or to improve the stability of a formulation; for example, where 
granules are coated with ethyl cellulose to inhibit oxidation. 
3) Modified-release tablet formulations may also be produced using ethyl cellulose 
as a matrix former 
Safety: Ethyl cellulose is widely used in oral and topical Pharmaceutical 
formulations. It is also used in food products. 
 
HYDROXY PROPYL METHYL CELLULOSE 4000:19 
Non Proprietary Name:  
   BP  :  Hypermellose 
   PhEur :  Methylhydroxypropylcellulosum 
    USP  :  Hydroxypropyl methyl cellulose 
Synonyms: Cellulose, hydroxypropyl methyl ether, methocel, ethylcellulose 
propylene glycol ether, methyl hydroxyl propylcelluloes metolose, pharmacoat. 
Description: Hydroxypropyl methylcellulose is an odourless and tasteless white or 
creamy white coloured fibrous or granular powder. 
Chemical Name: Cellulose, 2-Hydroxypropyl methyl ether. 
Functional Category: Coating agent, film former, stabilizing agent, suspending 
agent, tablet binder, viscosity increasing agent. 
Empirical Formula: The PhEur describes HPMC as a partly O-methylated and o-
(2-hydroxypropylated) cellulose. It is available in several grades which vary in 
viscosity and extent of substitution. HPMC defined in the USP XXII specifies the 
substitution type by appending a four digit number to the non proprietary name, 
e.g., hydroxypropyl methylcellulose 1828. The first two digits refer to the 
approximate percentage content of the methoxy group (OCH3). The second two 
digits refer to the approximate percentage content of the hydropropoxy group 
(OCH2CHOHCH3). 
Tapped Density :  0.05-0.70g/cm3 for pharmacoat. 
Melting Point  :  Browns at 190-2000C, chars at 225-2300C. 
Solubility: Soluble in cold water, forming a viscous colloidal solution, practically 
insoluble in chloroform, ethanol (95%) and ether, but soluble in mixtures of 
ethanol and dichloromethane. 
Stability and Storage: HPMC is a stable material although it is hygroscopic after 
drying. Solutions are stable between pH 3-11. Increasing temperature reduces the 
viscosity of solution. The gel point is 50-900C depending upon the grade of 
material. HPMC powder should be stored in a well-closed container, in a cool, dry 
place. 
Incompatibilities: It is incompatible with some oxidizing agents. Since it is non-
ionic, hydrolxypropyl methylcellulose will not   complex with metallic salt and 
ionic organics to form insoluble precipitates. 
Applications: Widely used in oral and topical pharmaceutical formulations. In oral 
products, it is primarily used as a tablet binder, in film coating and as an extended 
release tablet matrix. Concentrations of between 2-5% w/w may be used as a 
binder in either wet or dry granulation processes. It is also used a suspending agent 
and thickening agent in topical formulations, particularly ophthalmic preparations. 
Used as adhesive in plastic bandages and as wetting agent for hard contact lenses. 
 
GUGAR GUM19 
Non proprietary names: 
BP   : Guar galactomannan 
PhEur   : Guar galactomannum 
USPNF : Guar gum 
Synonyms: E412; Galactosol; guar flour; jaguar gum; meprogat; meprodor; 
meyprofin; meyproguar. 
Chemical name and CAS Registry number: Galactomannan polysaccharide  
          [9000-30-0] 
Empirical formula :  (C6H12O6)n 
Molecular weight  :  ≈ 220000 
Structural formula: Guar gum consists of linear chains of (1→4)-β-D-
mannopyranosyl units with α-D-galactopyranosyl units attached by (1→6) 
linkages. The ratio of D galactose to D-mannose is between 1:1.4 and 1:2 
Description: The USPNF 20 describes guar gum as a gum obtained from the 
ground endosperms of cyamopsis tetragonolobus (Fam: Leguminosae). 
Colour   : white to yellowish white 
Odour   : odorless or nearly odourless 
Taste    : bland taste 
Texture   : powder 
Acidity / Alkalinity  : pH 5.0 to 7.0 (1% w/v aqueous dispersion) 
Viscosity   : 4.86 Pas for 1% w/v dispersion 
Solubility: In organic solvents disperses and swells immediately in cold or hot 
water to form a highly viscous and thixotropic solution. 
Functional category: Suspending agent, Tablet binder, Tablet disintegrant, 
Viscosity increasing agent 
Applications in pharmaceutical technology: 
1) Used in solid dosage forms as a binder (up to 10%) and disintegrant 
2) Used in oral and topical products as a suspending, thickening (up to 2.5%) and 
stabilizing agent (1%) 
3) Used in colon targeted drug delivery systems 
4) Used as an appetite suppressant 
5) Also, used in cosmetic and food products 
Storage: Guar gum should be stored in a well closed container and kept in a cool 
and dry place. 
Incompatibilities: It is incompatible with acetone, alcohol, tannins, strong acids 
and alkalis. Presence of borate ions in distilled water, will prevents the hydration of 
guar gum. 
 
MICROCRYSTALLINE CELLULOSE 19 
Nonproprietary names: 
BP  : Microcrystalline cellulose 
JP  : Microcrystalline cellulose 
PhEur  : Cellulosum microcristallinum 
USPNF : Microcrystalline cellulose 
Synonyms: Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline 
cellulose; E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur. 
Chemical name and CAS Registry number: Cellulose [9004-34-6] 
Empirical formula and molecular weight: (C6H10O5)n ≈36 000. Where n ≈ 
220. 
Structural Formula: 
  
Functional Category: Adsorbent; Suspending agent; Tablet and Capsule Diluent; 
Tablet Disintegrant. 
Applications in pharmaceutical formulation or technology: Microcrystalline 
cellulose is widely used in pharmaceuticals, primarily as a binder/diluent in oral 
tablet and capsule formulations where it is used in both wet granulation and direct-
compression processes. In addition to its use as a binder/diluent, microcrystalline 
cellulose also has some lubricant and disintegrant properties that make it useful in 
tableting. Microcrystalline cellulose is also used in cosmetics and food products. 
Description: Microcrystalline cellulose is purified, partially depolymerised 
cellulose that occurs as a white, odourless, tasteless, crystalline powder composed 
of porous particles. It is commercially available in different particle sizes and 
moisture grades that have different properties and applications. 
Typical properties: 
Solubility: Slightly soluble in 5% w/v sodium hydroxide solution; practically 
insoluble in water, dilute acids, and most organic solvents. 
Stability and storage conditions: Microcrystalline cellulose is a stable though 
hygroscopic material. The bulk material should be stored in a well-closed container 
in a cool, dry place. 
Incompatibilities: Microcrystalline cellulose is incompatible with strong oxidizing 
agents. 
Safety: Microcrystalline cellulose is widely used in oral pharmaceutical 
formulations and food products and is generally regarded as a relatively nontoxic 
and non irritant material. Microcrystalline cellulose is not absorbed systemically 
following oral administration and thus has little toxic potential. Consumption of 
large quantities of cellulose may have a laxative effect, although this is unlikely to 
be a problem when cellulose is used as an excipient in pharmaceutical 
formulations. Deliberate abuse of formulations containing cellulose, either by 
inhalation or by injection, has resulted in the formation of cellulose granulomas. 
 
POLYVINYL PYRROLIDONE20 
Nonproprietary Names: 
BP :  Povidone 
USP :  Povidone 
Synonyms: Kollidon: Plasdone, polyvidone; polyvinylpyrrolidone, PVP. 
Chemical Name and CAS Registry Number: 1-Ethenyl-2-pyrrolidinone  
homopolymer [9003-39-8] 
Empirical Formula: (C6H9NO) n 
Molecular Weight: 2500–3 000 000 
Structural Formula: 
 
Functional Category: Disintegrant; dissolution aid; suspending agent; tablet 
binder. 
Description: Povidone occurs as a fine, white to creamy-white colored, odourless 
or almost odourless, hygroscopic powder. Povidones with K-values equal to or 
lower than 30 are manufactured by spray-drying and occur as spheres. 
Typical Properties: 
Solubility: Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, 
and water; practically insoluble in ether, hydrocarbons, and mineral oil. In water, 
the concentration of a solution is limited only by the viscosity of the resulting 
solution. 
Incompatibilities: Povidone is compatible in solution with a wide range of 
inorganic salts, natural and synthetic resins, and other chemicals. It forms 
molecular adducts in solution with Sulfathiazole, Sodium Salicylate, Salicylic 
Acid, Phenobarbital, Tannin, and other compounds. The efficacy of some 
preservatives, e.g. thiomersal, may be adversely affected by the formation of 
complexes with Povidone. 
Applications in Pharmaceutical Formulation or Technology: Although 
Povidone is used in a variety of pharmaceutical formulations, it is primarily used in 
solid-dosage forms. In tabletting, Povidone solutions are used as binders in wet-
granulation processes. Povidone is also added to powder blends in the dry form and 
granulated in situ by the addition of water, alcohol, or hydroalcoholic solutions. 
Povidone is used as a solubilizer in oral and parenteral formulations and has been 
shown to enhance dissolution of poorly soluble drugs from solid-dosage forms. 
Povidone solutions may also be used as coating agents. 
 
TALC 
Synonyms: Altalc; E553b; Hydrous Magnesium Calcium Silicate; Hydrous 
Magnesium Silicate; Luzenac Pharma; Magnesium Hydrogen Metasilicate; Magsil 
Osmanthus; Magsil Star; Powdered Talc; Purified French Chalk; Purtalc; 
Soapstone; Steatite; Superiore. 
Chemical Name and CAS Registry Number: Talc [14807-96-6] 
Empirical Formula and Molecular Weight: Talc is a purified, hydrated,   
magnesium silicate, approximating to the formula Mg6(Si2O5)4(OH)4. It may 
contain small, variable amounts of aluminium silicate and iron. 
Functional Category: Anticaking agent; Glidant; Tablet and Capsule Diluent; 
Tablet and Capsule Lubricant. 
Applications in Pharmaceutical Formulation or Technology: Talc was once 
widely used in oral solid dosage formulations as a lubricant and diluents. 
Description: Talc is a very fine, white to grayish-white, odourless, impalpable, 
unctuous, crystalline powder. It adheres readily to the skin and is soft to the touch 
and free from grittiness. 
Moisture content: Talc absorbs insignificant amounts of water at 25°C and 
relative humidities up to about 90%. 
Solubility: Practically insoluble in dilute Acids and Alkalis, Organic Solvents, and 
Water. 
Stability and Storage Conditions: Talc is a stable material and may be sterilized 
by heating at 160°C for not less than 1 hour. It may also be sterilized by exposure 
to ethylene oxide or gamma irradiation. Talc should be stored in a well-closed 
container in a cool, dry place. 
Incompatibilities: Incompatible with quaternary ammonium compounds. 
 
MAGNESIUM STEARATE 
Physico chemical properties 
Description: Magnesium stearate is a fine, white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the 
skin. 
Molecular Weight   : 591.34 
Structural Formula: CH3 (CH2)16COO] 2Mg 
Crystalline forms  : High-purity magnesium stearate has been isolated as a 
trihydrate, a dihydrate, and an anhydrate. 
Flowability  : poorly flowing, cohesive powder. 
Melting range : 117–150°C (commercial samples)126–130°C (high purity 
magnesium stearate) 
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%). 
Specific surface area: 1.6–14.8 m2/g 
Functional Category: Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation Technology: It is primarily used as 
a lubricant in capsule and tablet manufacture at concentrations between 0.25% and 
5.0% w/w. 
Incompatibilities: Incompatible with strong acids, alkalis, and iron salts. Strong 
oxidizing materials. Magnesium stearate cannot be used in products containing 
aspirin, some vitamins, and most alkaloidal salts. 
 
  
AIM AND PLAN OF WORK 
 
The main objective of the present study was to develop Compression coated tablets 
of carvedilol for Chronotherapeutic delivery. Carvedilol is used in the treatment of 
hypertension and angina pectoris. According to circadian rhythm (24hr- Biological 
clock) the Blood pressure (BP) will be more in early morning 3a.m – 6a.m because 
rennin, cortisol, angiotensin, aldosterone secretion is in peak level, most of the 
cardiovascular disorders such as Angina pectoris, sudden cardiac death, stroke, 
occurs at this time, the designed formulation to be taken at bed time and the focus 
is to optimally deliver the drug in higher amounts in early morning hours (i.e. at 
time of greatest need) and lower amounts at night (i.e. when the need of drug is 
less).  
 
Carvedilol is a highly lipophilic drug and is almost completely absorbed after oral 
administration. However, its bioavailability is very limited (25% to 35%) due to the 
hepatic first-pass effect. Its elimination half-life is also relatively short (about 6–8 
h). Therefore, it was chosen as a model drug for preparation of the once-daily 
controlled extended release dosage form. An oral time controlled release 
formulation facilitates the administration, just once a day to control the BP in 
patient with morning surge, which results in better compliance by patients and 
fewer side effects. The  present work was undertaken with the aims to achieve 
time-controlled release with distinct predetermined lag time by using  hydrophobic  
and hydrophilic  polymers. 
  
EXPERIMENTAL DESIGN 
 
Table 2: Materials used:  
SR 
NO MATERIALS 
MANUFACTURERS/ 
SUPPLIERS 
1.  Carvedilol Shasun Pharmaceuticals Ltd., Pondicherry. 
2.  Ethyl Cellulose S.D. Fine Chem. Ltd., Mumbai 
3.  Hydroxy Propyl Methyl Cellulose 4000 Ajantha Pharma, Mumbai 
4.  Polyvinylpyrrolidone Ajantha Pharma, Mumbai 
5.  Microcrystalline cellulose Loba Chemi Pvt., Ltd., Mumbai 
6.  Guar gum Himedia Laboratories. 
7.  Talc S.D. Fine Chem. Ltd., Mumbai 
8.  Magnesium Stearate S.D. Fine Chem. Ltd., Mumbai. 
 
  
Table 3: Equipment used: 
S. NO. INSTRUMENT MANUFACTURER/SUPPLIER 
1. Electronic Balance Sartorius, Germany. 
2. Rotary tablet Compression Machine (10 stages) Rimek Mini Press I. 
3. Hardness Tester Monsanto. 
4. Friability Test Apparatus Roche friabilator. 
5. Vernier Calliper Inox- Somet,Japan. 
6. 
Dissolution Apparatus. 
 
Electro Lab. (USP XX III)  
(DTD – 06P). 
7 Double BeamUV Spectrophotometer Systronic Corporation, Mumbai. 
8 FTIR Spectrophotometer Perkin Elmer Spectrum, Japan. 
10 Digital pH Meter Eutech Instruments, Japan. 
11 Hot Air Oven Kemi, Mumbai. 
12 Melting Point Apparatus. Kemi, Mumbai. 
13 Bulk Density Apparatus. Kemi, Mumbai. 
PREFORMULATION STUDIES 
Before formulation of drug substances into a dosage form, it is essential that it 
should be chemically and physically characterized. Preformulation studies give the 
information needed to define the nature of the drug substance and provide a frame 
work for the drug combination with pharmaceutical excipient in the fabrication of a 
dosage form. 
In the present work, preformulation studies on the development of calibration curve 
of the drug candidate and the compatibility between drug and excipient were 
carried out. 
Development of calibration curve for carvedilol:21 
Standard curve of carvedilol in acid buffer pH 1.2 
Accurately weigh 100 mg and dissolved in acid buffer of pH 1.2 in a 100 ml 
volumetric flask and the solution was made up to the volume with acid buffer of 
pH 1.2 to give 1000μg/ml solution. From the above solution 10 ml was diluted to 
100 ml using acid buffer of pH 1.2 to give 100μg/ml working stock solution. The 
above working stock solution was subsequently diluted with acid buffer of pH 1.2 
to obtain a series of dilutions containing 1, 2, 3, 4 and 5 μg/ml of solution. The 
λmax of the drug was determined by scanning the dilutions between 400 and 200 
nm using a  double beam UV-visible spectrophotometer (Systronic). At this 
wavelength, the absorbance’s of all the other solutions are measured using the acid 
buffer of pH 1.2 as blank. The concentrations of carvedilol and the corresponding 
absorbance values are given in table 14. The absorbance values were plotted 
against concentrations of carvedilol as shown in fig.1. The method obeys Beer-
Lambert’s law in the concentration range of 1-5 μg/ml. 
Preparation of pH 1.2 Hcl acid buffer 
Place 50 ml of the 0.2 M potassium chloride in a 200 ml volumetric flask, then add 
85 ml of 0.2 M hydrochloric acid and then add distilled water to make up the 
volume. 
Preparation of 0.2 M potassium chloride 
Dissolve 14.911 gm of potassium chloride in 1000 ml of distilled water. This will 
give 0.2 M potassium chloride. 
Preparation of 0.2 M hydrochloric acid 
Place 7.292 gm (17.8 ml) of hydrochloric acid in 1000 ml of distilled water, this 
will give 0.2 M HCl acid 
Table 4: Absorbance of carvedilol in acid buffer (pH 1.2) 
Concentration 
(μg/ml) 
Absorbance 
( nm) 
1 0.194 
2 0.360 
3 0.562 
4 0.729 
5 0.905 
 
 
Fig .4 Standard curve of carvedilol in acid buffer (pH 1.2) 
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Standard curve of carvedilol in phosphate buffer pH 6.8: 
 Accurately weigh 100 mg of carvedilol and dissolved in phosphate buffer of pH 
6.8 in 100 ml volumetric flask and the solution was made up to the volume with 
phosphate buffer of pH 6.8 to give 1000 μg /ml solution. From the above solution 
10 ml was diluted to 100 ml using phosphate buffer of pH 6.8 to give 100μg/ml 
working stock solution. The above working stock solution was subsequently 
diluted with phosphate buffer of pH 6.8 to obtain a series of dilutions containing 1, 
2, 3, 4 and 5 μg/ml of solution. The λmax of the drug was determined by scanning 
the dilutions between 400 and 200 nm using a double beam UV-visible 
spectrophotometer (Systronic). At this wavelength, the absorbance’s of all the other 
solutions are measured using the phosphate buffer of pH 6.8 as blank. The 
concentrations of carvedilol and the corresponding absorbance values are given in 
table 15. The absorbance values were plotted against concentrations of carvedilol 
as shown in fig.2. The method obeys Beer-Lambert’s law in the concentration 
range of 1-5 μg/ml. 
Preparation of pH 6.8 phosphate buffer  
Place 50 ml of the 0.2 M potassium dihydrogen phosphate solution in a 200 ml 
standard volumetric flask and add 22.4 ml of 0.2M sodium hydroxide solution to 
this flask and make up the volume with distilled water. 
Potassium dihydrogen phosphate, 0.2 M solution 
Take accurately weighed 27.22 gm of Potassium dihydrogen phosphate and 
dissolved in 1000 ml of distilled water, this will give 0.2 M KH2PO4. 
Sodium hydroxide 0.2 M solution 
Take accurately weighed 8 gm of sodium hydroxide and dissolved in 1000 ml of 
distilled water, this will give 0.2 M NaOH solution. 
  
Table 5: Absorbance of carvedilol in phosphate buffer (pH 6.8) 
Concentration 
(μg/ml) 
Absorbance 
( nm) 
1 0.23 
2 0.50 
3 0.750 
4 0.99 
5 1.2 
 
 
Fig.5 Standard curve of carvedilol in phosphate buffer (ph6.8) 
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Drug-excipient compatibility studies34 
In compression coated tablet formulation (in core) drug and polymer may interact 
as they are in close contact with each other, which could lead to the instability of 
drugs. Preformulatin studies regarding the drug-polymer interaction are therefore 
very critical in selecting appropriate polymer. FT-IR  (Perkin Elmer Spectrum, 
Japan.). spectroscopy was employed to ascertain the compatibility between 
carvedilol and the selected polymer. The pure drug and drug with excipient were 
scanned separately scanned in the range 4000-400 cm-1 (drug :polymer 1:1). 
potassium bromide was mixed with drug and/or polymer (in ratio 1:100) and 
compressed under 10-ton pressure in a hydraulic press to form a transparent pellet. 
The pellet was scanned from 4000-400 cm-1 and the spectra were taken. FT-IR 
spectrum of carvedilol was compared with FT-IR spectra of carvedilol with 
polymer disappearance of carvedilol peaks or shifting of peak in any spectra was 
studied 
Table 6: Assessment of the functional groups of carvedilol obtained in FT-IR 
spectra of compatibility studies.47  
S. N Functional group Standard ir range cm -1 
Assesment  peaks of 
pure drug cm -1 
1 
Secondary amine  (N-H 
stretching) 
3500-3300 3344.68 
2 Secondary alcohol 1350-1260 1305.85 
3 Aromatic 3050-3000 3058.24 
4 C-H 2960-2850 2923.22 
5 Aromatic hydrocarbons 1600 1606.76 
6 Disubstituted (ortho) 770-735 752.26 
7 -OCH3 stretching Below 3000 2923.22 
8 
C=C stretching in 
aromatic nuclei 
1700-1400 
1449.55, 1504.53, 
1589.40, 
1606.76,1629.90 
 
 
  Fig. 6 FTIR spectra of pure drug   
 
Fig. 7 FTIR spectra of HPMC 4000  
 
 
 
 
Fig. 8 FTIR spectra of pure drug +HPMC 4000  
 
Precompression Parameters : 22, 23, 29, 30, 31`, 32 
Angle of repose: The flow property of the powder drug was determined by 
measuring the Angle of Repose. It is the maximum angle that can be obtained 
between the free standing surface of a powder heap and the horizontal plane. 
Values of θ are rarely less than 20o, and values of up to 40o indicate reasonable 
flow potential. Above 50o, however, the powder flows only with difficulty if at all. 
  θ = Tan-1 (h/r) 
Where, 
h is height the pile. 
r is radius of the pile. 
θ is angle of repose. 
A funnel was fixed in a holder; the tip of the funnel was placed at a height of 6 cm 
from the surface. A graph sheet was placed below the funnel. 5 gms of the sample 
were taken and were passed slowly through the funnel. The height of the powder 
heap formed was measured. The circumference of the heap formed was drawn with 
a pencil on the graph paper. The radius was determined and the angle of response 
was determined using the given formula. The same procedure was repeated 3 times 
for each sample. 
Determination of bulk density and tapped density: 20 g of the powder (W) from 
each formula was introduced individually into a 100ml of measuring cylinder. 
After that the initial volume was noted, the cylinder was kept in bulk density 
apparatus for tapping. The tapping was continued for 100 times and the change in 
volume was noted. 
The bulk density, and tapped density were calculated using the following 
formulas: -  
                      Bulk density = W / V0 
                 Tapped density = W / Vf 
Where, 
W is weight of the powder. 
V0 is initial volume. 
Vf is final volume. 
The results were presented in the table:7 
Compressibility index (Carr’s index): Compressibility index is an important 
measure which can be obtained from bulk and tapped densities. Theoretically, the 
less compressible a material the more flowable it is. 
This shows that a material having value of less than 18 % is defined as the free 
flowing material. 
CI   = 100 (V0  - Vf) /  V0 
Where, 
           CI   is compressibility index. 
Haussner’s Ratio: This indicates the flow properties of the powder and is 
measured by the ratio of tapped density to the bulk density. 
 Hauser’s Ratio = (W / Vf  ) / (W / V0) 
Where, 
 W / Vf = Tapped density.  
 W / V0 is Bulk density.  
Thus, 
Haussner’s Ratio = Tapped density/Bulk density. 
Table 7: precompression parameters of core tablets F1-F9 
Formulation 
code 
Angle of 
repose 
Bulk 
density 
(gm/cm2) 
Tapped 
density 
(gm/cm2) 
Compressibility 
index (%) 
haussner’s 
ratio 
F1 24.07 0.660 0.625 18.98 1.03 
F2 21.84 0.530 0.585 17.24 1.05 
F3 23.98 0.516 0.592 19.51 1.19 
F4 24.63 0.484 0.579 19.11 1.16 
F5 24.41 0.464 0.606 15.99 1.18 
F6 23.14 0.457 0.597 11.41 1.12 
F7 25.32 0.502 0.516 14.39 1.08 
F8 26.26 0.499 0.619 12.40 1.16 
F9 24.31 0.506 0.721 17.58 1.17 
 
  
Table 8: Precompression parameters of coated material powder blend F1-F9 
Formulation 
Code 
Angle 
of 
Repose 
Bulk 
Density 
(gm/cm2) 
Tapped 
Density 
(gm/cm2) 
Compressibility 
Index (%) 
Haussner’s 
Ratio 
F1 23014” 0.740 0.869 14.814 1.174 
F2 25042” 0.714 0.800 10.714 1.120 
F3 24033” 0.689 0.769 10.344 1.116 
F4 25045” 0.769 0.869 11.538 1.130 
F5 26038” 0.714 0.833 14.285 1.166 
F6 24034” 0.689 0.800 13.793 1.161 
F7 23044” 0.769 0.869 11.538 1.130 
F8 26036” 0.740 0.833 11.111 1.125 
F9 24044” 0.714 0.833 14.285 1.166 
 
Formulation of Compression -Coated tablets of Carvedilol40, 43 
The different formulations of carvedilol controlled onset extended release tablets 
were formulated by press-coating technique under direct compression method 
using a combination of hydrophobic polymer ethylcellulose, hydrophilic polymer 
polyvinylpyrrolidone, and natural swellable polymer guar gum as outer coating 
layer. 
Formulation of Core Tablets 
The core tablets containing drug, HPMC and MCC, were prepared by weighing all 
the ingredients and passed through sieve no.80 and mixed in a geometrical dilution 
method. Magnesium stearate and talc (1% each) were added to each blend and 
further mixed. The resultant blends were tableted to 60 mg using 7/32 flat punches 
in a rotary tabletting machine (Rimek minipress, India). 
Compression -Coating of Core Tablet 
The composition of the tablets is given in Table 9. Ethyl cellulose (EC) and each 
mixture of polyvinylpyrrolidone and guar gum were passed through a sieve no.80 
and 90 mg of the powder mixture was used for the outer shell. Different weight 
ratios of (w/w) of EC/excipient mixture were formulated as shown in Table 7 & 8. 
The press-coating of tablets was performed using 9/32 concave punches in a rotary 
tabletting machine (Rimek minipress, India). A half amount of the EC/excipient 
mixture was filled into the die to make a powder bed, on the centre of which was 
placed the core tablet. Then, the remaining half of the EC/excipient mixture was 
filled in the die and the contents were compressed to prepare the compression-
coated tablet. 
The hydrophilic gums are extensively used for oral extended release dosage forms 
due to their simplicity, cost effectiveness and reduction of the risk of systemic 
toxicity due to dose dumping. Furthermore, pH-independent drug release is 
preferable for oral extended release formulations, so as not to be affected by intra- 
and inter-subject variations of both gastric pH and GI transit time. The 
hydroxypropylmethylcellulose (HPMC) is a pH-independent material and the drug 
release rates from HPMC matrix formulations are generally independent of 
processing variables such as compaction pressure, drug particle size, and the 
incorporation of a lubricant .Therefore, HPMC is widely used to prepare extended 
release dosage forms. 
Table 9: The composition and formulation code for various tablets containing 
Carvedilol 
S. 
No. 
Ingredients 
mg/tab 
Formulation code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1. Carvedilol 25 25 25 25 25 25 20 30 25 
2. HPMC 20 20 20 20 20 20 20 20 35 
3. Microcrystalline Cellulose q.s q.s q.s q.s q.s q.s q.s q.s q.s 
4. Ethyl cellulose 45 60 30 45 60 30 45 45 45 
5. PVP 45 30 60 _ _ _ 45 45 45 
6. Guar gum _ _ _ 45 30 60 _ - _ 
7. Magnesium Stearate q.s q.s q.s q.s q.s q.s q.s q.s q.s 
8. Talc q.s q.s q.s q.s q.s q.s q.s q.s q.s 
Table 10: The composition and formulation code of various Compression 
coated tablet containing Carvedilol using EC & PVP outer coat. 
S. NO. 
Formulation 
Code 
EC PVP In ratios 
1 F1 45 45 1:1 
2 F2 60 30 2:1 
3 F3 30 60 1:2 
4 F7 45 45 1:1 
5 F8 45 45 1:1 
6 F9 45 45 1:1 
 
Table 11: The composition and formulation code of various PCT containing 
Carvedilol using EC & guar gum as outer coat. 
S. NO FormulationCode EC Guar gum In ratios 
1 F4 45 45 1:1 
2 F5 60 30 2:1 
3 F6 30 60 1:2 
 
EVALUATION OF CORE AND PRESS COATED TABLET:24 
The above core and press coated tablet were evaluated for physical properties like: 
Thickness, Hardness, Friability, Weight variation, Drug content uniformity, 
Compatibility studies and In vitro dissolution studies  
Tablet Thickness: The thickness of the tablet was measured with Vernier Calliper. 
Three tablets were selected from each formulations and the test was performed.  
Hardness Test: Hardness test was carried out by using “Monsanto” hardness 
tester. Three tablets were randomly selected from each of the formulations and the 
test was carried out.  
Friability Test: “Roche” friabilator is used to determine the friability of the 
tablets. For determining the friability of the tablets six tablets were taken and 
weighed. After weighing the tablets were placed in the Roche friabilator and was 
allowed for the combined effects of abrasion and shock by utilizing a plastic 
chamber which was then allowed to revolve at 25 rpm for 4 minutes, this drops the 
tablets from a height of six inches with each revolution. After undergoing this 
procedure the tablets were dedusted and reweighed.  
Friability can be determined by  
 
Where, 
 Wo is weight of tablets before friability test. 
 Wt is weight of tablets after friability test.  
Weight Variation Test: Ten tablets were selected at random and the average 
weight was determined. Not more than two of the individual tablet’s weights 
should deviate from the average weight by more than the percentage deviation 
shown in table and none should deviates by more than twice the percentage.  
Table 12: Standard data of percentage deviation of tablets as per USP 
Pharmaceutical 
Form Average mass % Deviation 
Tablets 
≤130 mg ± 10 
> 130 mg - 324 mg ± 7.5 
≥ 325 mg ± 5 
% Maximum positive deviation = (WH –A/ A) x 100 
% Minimum negative deviation = (A-WL/ A) x 100 
Where,   
WH  is highest weight in mg. 
WL  is lowest weight in mg. 
            A is average weight of tablet in mg. 
Drug Content of Core Tablets: Five tablet from each batch was powdered 
individually and a quantity equivalent to 25 mg of Carvedilol was weighed and 
dissolved in a suitable volume of phosphate buffer (6.8 pH). After making suitable 
F = 100 (1‐Wt/Wo) 
dilutions the absorbance of the solution was measured against the corresponding 
blank at 285 nm using a double beam UV/Visible spectrophotometer 
Table 13: Evaluation of Core-Tablet 
S 
No 
Formulation 
code 
Hardness 
(kg/cm2) 
Friability 
(%) 
Average 
thickness 
in mm 
weight 
variation 
mg 
%Drug 
content 
1 F1 3.1 0.355 1.89 61 91.66 
2 F2 2.9 0.361 2.1 60 99.33 
3 F3 3.0 0.328 1.95 60 93.66 
4 F4 2.8 0.289 2.11 61 93.66 
5 F5 2.9 0.321 1.99 58 94.33 
6 F6 3.1 0.310 1.94 59 96.33 
7 F7 2.8 0.348 1.90 61 92.66 
8 F8 3.0 0.308 2.0 59 95.00 
9 F9 3.2 0.360 2.14 58 94.00 
 
Table 14: Evaluation of press coated tablet containing carvedilol using 
EC/PVP as an outer coat 
S. No. Formulation Code 
Hardness 
(kg/cm2) 
Friability 
(%) 
Average 
thickness 
in mm 
weight 
variation 
mg 
1 F1 5.1 0.14 3.22 153 
2 F2 5.2 0.19 3.30 152 
3 F3 5.4 0.06 3.32 153 
4 F7 5 0.14 3.58 150 
5 F8 4.9 0.56 3.27 154 
6 F9 5.7 0.56 3.35 155 
 
  
Table 15: Evaluation of press coated tablet containing Carvedilol using 
EC/Guar gum as an outer coat. 
S. No. Formulation Code 
Hardness 
(kg/cm2) 
Friability 
(%) 
Average 
thickness 
in mm 
weight 
variation 
mg 
1 F4 5.6 0.03 3.52 154 
2 F5 5.3 0.11 3.46 151 
3 F6 5.4 0.09 3.37 153 
 
In vitro drug release study of press coated tablets40 In-vitro dissolution studies 
were performed on nine different press coated tablets prepared by direct 
compression method at 37o ± 0.5 °C using 900 ml of acid buffer (1.2 pH) for two 
hours followed by 900 ml of phosphate buffer (6.8 pH) as dissolution media for 
twenty two hours in USP apparatus II with the paddle speed 50 rpm. 5 ml of 
filtered aliquot was withdrawn at pre-determined time intervals 
(1,2,3,4,5,6,7,8,12,16,20,24 hours) and replaced with 5 ml of fresh 1.2 pH acid 
buffer and 6.8 pH phosphate buffer solution respectively, maintained at the same 
temperature. The samples were analyzed at 285 nm using a UV spectrophotometer. 
The amount of carvedilol dissolved in the dissolution media was then determined 
from the calibration curve. The lag time and percentage release of carvedilol was 
determined for the each formulation. 
Details of dissolution test: 
Dissolution test apparatus  :  USP type II  
Speed     :  50 rpm 
Stirrer     :  Paddle type 
Volume of medium   :  900 ml 
Aliquot taken at each time interval :  5 ml 
            Medium used                            :  Acid buffer (pH 1.2),        
                                                                     :   Phosphate buffer (pH 6.8). 
Temperature    :  37 ± 0.5 0C 
 Table 16: Percentage In vitro Release profileof Carvedilol containing 
EC/PVP/Guar gum using Various Buffers. 
Time 
(hrs) 
Percentage release of Carvedilol from PCT 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 0 0 0 0 0 2.3 0 0 0 
2 0 0 0 2.9 0 6.7 0 0 0 
3 0 0 3.6 8.5 0 8.3 0 0 0 
4 6.6 0 6.7 11.7 0 18.9 3.7 4.7 3.4 
5 17.3 0 14.6 23.7 0 31.3 10.1 8.6 7.0 
6 30.8 13.2 25.1 35.8 14.4 44.3 22.6 24.2 18.8 
7 38.3 25.1 36.4 54.2 29.2 52.8 30.9 33.2 26.5 
8 43.6 37.6 48.0 74.3 39.6 69.2 41.2 41.2 33.9 
12 70.2 67.2 67.6 84.3 69.3 84.3 72.7 72.7 62.9 
16 78.4 80.9 85.3 94.1 80.6 97.4 81.7 84.6 76.3 
20 88.1 91.5 98.8 99.3 94.2 - 92.9 90.1 84.9 
24 96.5 99.3 - - 98.1 - 99.3 98.1 96.5 
 
  
 Table 17: Dissolution profile of formulation F1* containing Carvedilol using 
buffer pH 1.2 and 6.8 
Time (hr) Absorbance (290 nm) 
Amount 
(μg/ml) 
Amount 
(mg/900ml) 
Cumulative 
%release 
1 0.000 0 0 0 
2 0.000 0 0 0 
3 0.000 0 0 0 
4 0.0453 1.85 1.67 6.68 
5 0.1175 4.81 4.33 17.3 
6 0.2084 8.54 7.68 30.88 
7 0.2536 10.56 9.51 38.3 
8 0.2922 11.97 10.77 43.6 
12 0.4709 19.29 17.36 70.2 
16 0.5242 21.48 19.33 78.48 
20 0.5869 24.05 21.64 88.16 
24 0.6402 26.23 23.61 96.5 
 
 
Fig 9 in vitro drug release profile of carvedilol F1 (EC:PVP1:1) 
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Table 18: Dissolution profile of formulation F2* containing carvedilol using 
buffer pH 1.2 and 6.8 
Time 
(hr) 
Absorbance (290 
nm) 
Amount 
(μg/ml) 
Amount 
(mg/ 900ml)
Cumulative 
%release 
1 0 0 0 0 
2 0 0 0 0 
3 0 0 0 0 
4 0 0 0 0 
5 0 0 0 0 
6 0.09 3.68 3.31 13.27 
7 0.17 6.96 6.27 25.15 
8 0.2536 10.39 9.35 37.62 
12 0.4532 18.57 16.71 67.28 
16 0.5432 22.26 20.03 80.93 
20 0.612 25.08 22.57 91.53 
24 0.661 27.09 24.38 99.3 
 
 
Fig. 10 in vitro drug release profile of carvedilol F2 (EC:PVP2:1) 
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Table 19: Dissolution profile of formulation F3* containing carvedilol using 
buffer pH 1.2 and 6.8 
Time (hr) Absorbance (290 nm) 
Amount 
(μg/ml) 
Amount 
(mg/900ml) 
Cumulative 
%release 
1 0 0 0 0 
2 0 0 0 0 
3 0.025 1.02 0.92 3.68 
4 0.0453 1.85 1.67 6.70 
5 0.099 4.05 3.65 14.66 
6 0.1698 6.95 6.29 25.19 
7 0.245 10.04 9.03 36.42 
8 0.3224 13.21 11.89 48.04 
12 0.4532 18.57 16.71 67.60 
16 0.571 23.40 21.06 85.36 
20 0.659 27.00 24.30 98.81 
24 - - - - 
 
 
Fig. 11 In vitro drug release profile of carvedilol F3 (EC:PVP 1:2) 
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Table 20: Dissolution profile of formulation F4* containing carvedilol using 
buffer pH 1.2 and 6.8 
Time (hr) Absorbance (290 nm) 
Amount 
(μg/ml) 
Amount 
(mg/900ml) 
Cumulative 
%release 
1 0 0 0 0 
2 0.0416 0.80 0.72 2.90 
3 0.0579 2.37 2.13 8.55 
4 0.0789 3.23 2.91 11.70 
5 0.1598 6.54 5.89 23.70 
6 0.241 9.87 8.88 35.81 
7 0.3644 14.93 13.44 54.22 
8 0.4988 20.44 18.39 74.34 
12 0.564 23.11 20.80 84.37 
16 0.627 25.69 23.12 94.13 
20 0.659 27.00 24.84 99.3 
24 - - - - 
 
 
Fig. 12 in vitro drug release profile of carvedilol F4 (EC:GUAR 1:1) 
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Table 21: Dissolution profile of formulation F5* containing carvedilol using 
buffer pH 1.2 and 6.8 
Time (hr) Absorbance (290 nm) 
Amount 
(μg/ml) 
Amount 
(mg/900ml) 
Cumulative 
%release 
1 0 0 0 0 
2 0 0 0 0 
3 0 0 0 0 
4 0 0 0 0 
5 0 0 0 0 
6 0.09 4.02 3.62 14.48 
7 0.198 8.11 7.30 29.29 
8 0.267 10.94 9.84 39.63 
12 0.467 19.13 17.22 69.36 
16 0.541 22.17 19.95 80.66 
20 0.630 25.83 23.25 94.29 
24 0.653 26.76 24.08 98.14 
 
 
 
Fig.13 in vitro drug release profile of carvedilol F5 (EC:GUAR GUM 2:1) 
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Table 22: Dissolution profile of formulation F6* Containing carvedilol using 
buffer pH 1.2 and 6.8 
Time 
(hr) 
Absorbance 
(290 nm) 
Amount 
(μg/ml) 
Amount 
(mg/900ml) 
Cumulative 
%release 
1 0.012 0.66 0.59 2.38 
2 0.0305 1.68 1.51 6.07 
3 0.056 2.29 2.07 8.30 
4 0.127 5.22 4.72 18.90 
5 0.211 8.64 7.78 31.32 
6 0.298 12.22 10.99 44.36 
7 0.354 14.50 13.05 52.84 
8 0.463 18.97 17.07 69.21 
12 0.563 23.07 20.76 84.34 
16 0.649 26.59 23.93 97.4 
20 - - - - 
24 - - - - 
 
 
 
 
Fig.14 in vitro drug release profile of carvedilol F6 (EC:GUAR GUM 1:2) 
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Table 23: Dissolution profile of formulation F7* containing carvedilol using 
buffer pH 1.2 and 6.8 
Time 
(hr 
Absorbance 
(290 nm) 
Amount 
(μg/ml) 
Amount 
(mg/900ml) 
Cumulative 
%release 
1 0 0 0 0 
2 0 0 0 0 
3 0 0 0 0 
4 0.025 1.03 0.93 3.73 
5 0.068 2.82 2.54 10.18 
6 0.153 6.27 5.64 22.65 
7 0.208 8.54 7.68 30.95 
8 0.277 11.36 10.22 41.27 
12 0.489 20.04 18.18 72.74 
16 0.547 22.41 20.42 81.70 
20 0.62 25.40 23.23 92.92 
24 0.66 27.04 24.34 99.33 
 
 
Fig.15 in vitro drug release profile of carvedilol F7(EC:PVP 1:1) 
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Table 24: Dissolution profile of formulation F8* containing carvedilol using 
buffer pH 1.2 and 6.8 
Time (hr) Absorbance (290 nm) 
Amount 
(μg/ml) 
Amount 
(mg/900ml) 
Cumulative 
%release 
1 0 0 0 0 
2 0 0 0 0 
3 0 0 0 0 
4 0.032 1.31 1.18 4.72 
5 0.058 2.40 2.16 8.68 
6 0.164 6.72 6.04 24.27 
7 0.224 9.18 8.26 33.25 
8 0.277 11.36 10.22 41.29 
12 0.489 20.04 18.19 72.76 
16 0.567 23.23 20.91 84.67 
20 0.601 24.63 22.16 90.15 
24 0.652 26.72 24.04 98.17 
 
 
Fig.16 in vitro drug release profile of carvedilol F8 (EC:PVP1:1) 
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Table 25: Dissolution profile of formulation F9* containing carvedilol using 
buffer pH 1.2 and 6.8 
Time 
(hr) 
Absorbance 
(290 nm) 
Amount 
(μg/ml) 
Amount 
(mg/900ml) 
Time 
(hr) 
1 0 0 0 0 
2 0 0 0 0 
3 0 0 0 0 
4 0.023 0.94 0.85 3.40 
5 0.047 1.5 1.76 7.07 
6 0.127 5.22 4.70 18.86 
7 0.178 7.32 6.59 26.54 
8 0.288 9.34 8.40 33.94 
12 0.423 17.33 15.60 62.94 
16 0.511 20.94 18.84 76.23 
20 0.567 23.23 20.91 84.91 
24 0.643 26.35 23.71 96.59 
 
 
Fig. 17 in vitro drug release profile of carvedilol F9 (EC:PVP1:1) 
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 Fig.18 in vitro drug release profile of carvedilol F1-F9 coated with PVP/EC/guar 
gum 
 
Kinetic Analysis of in-vitro Release Rates of Compression Coated Carvedilol 
Tablet: 26 
In order to define the transport mechanisms and type of release, four kinetic models 
where applied the zero order rate Eq. (1) describes the systems where the drug 
release rate is independent of its concentration. The first order Eq. (2) describes the 
release from system where release rate is concentration dependent. Higuchi 
described the release of drugs from insoluble matrix as a square root of time 
dependent process based on Fickian diffusion Eq. (3). Korsmeyer  derived a simple 
relationship which described drug release from a polymeric system Eq. (4). To find 
out the mechanism of drug release, drug release data was fitted in Korsmeyer–
Peppas model 
The result of in vitro release profile obtained for optimized formulations F2 were 
plotted in mode of data treatment as follows: -  
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F1 EC:PVP (1:1)
F2EC:PVP(2:1) BEST
F3EC:PVP(1:2)
F4EC:GUARGUM(1:1)
F5EC:GUGARGUM(2:1)
F6EC:GUGARGUM(1:2)
F7 EC:PVP(1:1)
F8EC:PVP(1:1)
F9 EC:PVP (1:1)
1. Zero - order kinetic model: This follows, Cumulative % drug released Vs 
time. 
2. First – order kinetic model: This follows, Log cumulative percent drug 
remaining Vs time. 
3.  Higuchi’s model: This follows, Cumulative percent drug released Vs 
square root of time. 
4. Korsmeyer equation / Peppa’s model: This follows, Log cumulative percent 
drug released Vs log time. 
Zero order kinetics:  
Zero order release would be predicted by the following equation: - 
 At = A0 – K0t 
Where,  
 At  Is Drug release at time‘t’. 
 A0 = Initial drug concentration. 
  K0 = Zero - order rate constant (hr-1). 
When the data is plotted as cumulative percent drug release Vs time, if the plot is 
linear then the data obeys Zero – order kinetics and its slope is equal to Zero order 
release constant K0. 
First Order Kinetics: 
First – order release would be predicted by the following equation: - 
Log C = log C0 – Kt / 2.303 
Where,  
C   = Amount of drug remained at time‘t’. 
C0  = Initial amount of drug. 
K   = First – order rate constant (hr-1). 
When the data plotted as log percent drug remaining Vs time, yields a straight line, 
this indicates that the release follows first order kinetics. The constant ‘K1’ can be 
obtained by multiplying 2.303 with the slope value. 
Higuchi’s model: 
Drug release from the matrix devices by diffusion has been described by following 
Higuchi’s classical diffusion equation: - 
Q = [Dε / τ (2 A - εCs) Cst] ½ 
Where, 
Q = Amount of drug released at time‘t’. 
D = Diffusion coefficient of the drug in the matrix. 
A = Total amount of drug in unit volume of matrix. 
Cs = the solubility of the drug in the matrix. 
ε = Porosity of the matrix. 
τ = Tortuosity. 
t = Time (hrs) at which ‘q’ amount of drug is released. 
Above equation may be simplified if one assumes that ‘D’, ‘Cs’ and ‘A’ are 
constant. Then equation becomes: - 
Q = Kt1/2 
When the data is plotted according to equation i.e. cumulative drug release Vs 
square root of time yields a straight line, this indicates that the drug was released 
by diffusion mechanism. The slope is equal to ‘K’ (Higuchi’s 1963). 
Korsmeyer equation / Peppa’s model:  
To study the mechanism of drug release from the sustained-release matrix tablets 
of Diltiazem Hydrochloride, the release data was fitted to a well-known 
exponential equation (Korsmeyer equation/ peppa’s law equation), which is often 
used to describe the drug release behavior from polymeric systems. 
Mt / Mα = Ktn 
Where, 
Mt / Mα = The fraction of drug released at time‘t’. 
K = Constant incorporating the structural and geometrical characteristics of 
the drug / polymer system. 
n = Diffusion exponent related to the mechanism of the release. 
Above equation can be simplified by applying log on both sides, 
And we get: -  
   Log Mt / Mα = Log K + n Log t 
Table 26: Mechanism of drug release as per korsmeyer equation / peppa’s 
model. 
S. No. n Value Drug release 
1.  < 0.45 Fickian release 
2.  0.45 <1.0 Non – Fickian release 
3.  > 1.0 Class II transport 
When the data is plotted as log of % cumulative drug released Vs log time, it yields 
a straight line with a slope equal to ‘n’. For Fickian release ‘n’ = 0.45 while for 
anomalous (non - Fickian) transport ‘n’ ranges between 0.45 and 1.0.  
Table 27: Drug release kinetics study of optimize batch F2 
Time 
(hr) 
%drug 
release 
% drug 
remaining 
Log % drug 
remaining logt 
Square 
root of t 
Log % 
drug 
release 
1 0 100 2 0 1 - 
2 0 100 2 0.3010 1.4142 - 
3 0 100 2 0.4771 1.7320 - 
4 0 100 2 0.6020 2 - 
5 0 100 2 0.6989 2.2360 - 
6 13.27 86.72 1.9381 0.7781 2.4494 1.123 
7 25.15 74.84 1.8742 0.8450 2.6457 1400 
8 37.62 62.37 1.7950 0.9030 2.8284 1.575 
12 67.28 32.71 1.5147 1.0791 3.4641 1.827 
16 80.93 19.06 1.2802 1.2041 4 1.908 
20 91.53 8.46 0.9277 1.3010 4.4721 1.961 
24 99.3 0.70 -0.1331 1.38021 4.8989 1.996 
  
Fig. 19 Shows zero order kinetics of F2 
 
Fig.20 Shows first order kinetics of F2 
 
Fig. 21 Shows higuchi model for F2 
 
Fig. 22 Shows  peppa’s model for F2 
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Table 28: Result of model fitting of batch F2 
Formulation 
Zero 
Order R2 
First 
Order R2 
Higuchi 
model R2 
Korsmeyer's 
Plot R2 
F2 0.9392 0.8826 0.9252 0.8878 
  n=1.322 
 
Transverse and longitudinal section view of press coated tablets33 
Tablets were cut transversely and longitudinally by using blade individually. The 
cutting sections of tablets were evaluated by digital camera. 
 
 
 
Fig.23 shows the external appearance of the press coated tablets of formulation 
 
                                      
     Transverse section view                                   Longitudinal section view 
Fig .24 Transverse and longitudinal section view of press coated tablets. 
 
  
Stability Studies of the Optimized Formulation35 
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under influence of a variety of 
environmental factors such as temperature, humidity and light, and enables 
recommended storage conditions, re-test periods and shelf-lives to be established. 
ICH specifies the length of study and storage conditions: 
Long term testing: 250C ± 20C /60% RH ± 5% RH for 12 months. 
Method 
Accelerated testing: 400C ± 20C /75% RH ± 5% RH for 6 months. 
In the present study, stability studies were carried out at 400C ± 20C for a time 
period of 90 days for selected optimized formulations. 
For stability study, the tablets were placed in amber colored vials and sealed with 
aluminum foil. These sample containers were placed in desiccators. 
Evaluation of samples: The samples were analyzed for the following parameter, 
Physical evaluation: 
Appearance: The samples were checked for any change in color at every week. 
Hardness: The samples were tested for hardness at every week. 
Chemical evaluation: 
Drug content: The samples were checked for drug content. 
Drug release: The samples were subjected to drug release studies. 
  
 
Table 29: in vitro drug release study of F2 optimized bacth 
Time in 
hours 
F2 
Zero month 
F2 
1stmonth 
F2 
2nd month 
F2 
3erd month 
1 0 0 0 0 
2 0 0 0 0 
3 0 0 0 0 
4 0 0 0 0 
5 0 0 0 0 
6 13.27 13.52 13.75 13.89 
7 25.15 25.61 26.12 26.12 
8 37.62 37.62 37.89 37.91 
12 67.28 67.43 67.64 67.71 
16 80.93 81.0 81.2 81.25 
20 91.53 91.72 91.98 92.1 
24 99.3 99.1 98.9 98.7 
 
 
Fig. 25 in vitro drug release study of F2 optimized batch 
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Table 30: Different Parameters of stability study 
Paramater 
At temp400±20c RH 75%±5% 
F2 zero 
month 
F2 
1st month 
F2 
2nd month 
F2 
3ed month 
apprance Off white Off white Off white Off white 
Weight(mg) 152 No change No change No change 
Thickness(mm) 3.30 No change No change No change 
Hardness(kg/cm2) 5.2 No change No change No change 
% drug content 99.33 99.03 98.79 98.23 
% drug release 99.3 99.1 98.9 98.7 
 
 
  
DISCUSSION 
The aim of this work was to develop a chronotherapeutic delivery of carvedilol in 
the form of press coated tablets. In this study we develop a chronological dosage 
form to release the drug in the early morning between 3a.m to 6a.m because rennin, 
cortisol, angiotensin, aldosterone were secreted in peak level, most of the 
cardiovascular disorders such as angina pectoris, sudden cardiac death, stroke 
occurs in this time, the designed formulation was planned to taken at bedtime and 
the focus was to optimally deliver the drug in higher amounts in the early morning 
hours and lower amount at night.  
The prepared press coated tablets (F1 to F9) were used for evaluation of 
compatibility studies, physico-chemical parameters such as hardness, friability, 
thickness, weight variation, drug content uniformity, in vitro release and in vitro 
release kinetics. 
PREPARATION OF STANDARD CURVE OF CARVEDILOL: 
From the standard curve of Carvedilol it was observed that the drug obeys beer’s 
law in concentration range of 1-5 µg/ml in acid buffer (pH 1.2) and phosphate 
buffer (pH6.8). 
COMPATIBILITY STUDIES 
The compatibility studies between the drugs and excipient were evaluated by using 
IR matching approach. The IR spectrum of excipient with drug was compared with 
the standard spectrum of carvedilol. In carvedilol IR spectrum, principal peaks 
were noticed at following wave numbers 3344.68, 1305.24,3058.24, 2923.22, 
1696.76, 752.26,2923.22 cm-1 (KBr pellet). There was no appearance or 
disappearance of characteristics peaks. The IR spectra obtained are given in fig 6,7 
and 8. This method confirms the absence of any chemical interaction between drug 
and excipient. 
  
Formulation: 
Nine different press coated tablets of carvedilol were formulated by using various 
proportions of different polymers such as HPMC, ethyl cellulose, 
polyvinylpyrrolidone and guar gum by direct compression method. All the 
formulations were prepared by keeping constant tablet weight (150mg ± 15mg) and 
hardness (5.2 ± 0.5 kg/cm2). 
EVALUATION PARAMETERS: 
Physicochemical Evaluation: 
The blend powder of all the batches exhibited good flow characteristics evident 
from the results of their physicochemical evaluations. The angle of repose value 
ranged from 23.14” to 26.26” for core and 23014” to 26038”for coating material. 
The results were found to be below 280 and hence the blend showed to have good 
flow ability. Bulk and tapped densities are used for the measurement of 
Compressibility index. The Bulk density ranged from 0.057to 0.660 for core and 
0.689 to 0.769 for coating material. 
While tapped density ranged from 0.578 to 0.721for core and 0.769 to 0.869 for 
coating material. The compressibility index (%) was calculated from the Bulk 
density and it ranged from 11.41 to 19.51 for core and 10.344 to 14.814 for coating 
material. The blend was found to have free flowing property as the result were 
found to be below 20%. The Haussner’s ratio ranged from 1.03 to 1.18 for core and 
1.116 to 1.174 for coating material. The result indicates the free flowing properties 
of the powder as the value was below 1.2. (table 7 & 8) 
The prepared tablets were subjected to evaluation tests such as hardness, thickness, 
% weight variation, friability and drug content. All the nine formulations had 
shown results for these characteristics within the acceptable ranges.(table 13,14 & 
15)  
IN VITRO DRUG RELEASE PROFILE: 
From the results of in vitro studies all the prepared press-coated tablets (F1 to F9) 
were given a good release in the range of 96.5% w/v to 99.3% w/v. The 
formulation F2 [25mg of carvedilol, EC: PVP (2:1)] and F5 [25mg of carvedilol, 
EC: Guar gum (2:1)] were shown ideal release for chronotherpeutics. Because of 
having a lag time of 5 hours and maximum release of 99.3 % w/v and 98.1 % w/v 
respectively. The in vitro dissolution data are given in Table 18 and 21 and fig. 10 
and 13 respectively. 
The profiles clearly indicate that the carvedilol released from the press coated tablet 
exhibited a unique release profile depending on the amount of PVP and EC used 
and also HPMC polymer in core tablet contributes in drug release for prolonged 
period. The profile exhibited a lag time (induction period) followed by a prolonged 
drug release throughout a day. The drug was released from the press-coated tablet 
after a lag period of 5-6 hours, depending upon the weight ratios of EC and PVP. 
The swelling of the outer shell of press-coated tablets is a key factor to achieve the 
time-controlled delivery. The drug was released from the core tablet after 
rupturing, caused by the pressure build up with in the core system. Increasing the 
concentration of EC in the formulation of the outer shell, the lag time was 
increased. The lag time changed according to weight ratios of the EC and PVP as 
follows. F3 < F1 < F2 
The dissolution profile of EC/guar gum was also similar to that of the dissolution 
profile of EC/PVP, showing a distinctive inducting lag followed by drug release. 
The lag time of the press coated tablets containing (1:1, 2:1, 1:2) ratios of EC/guar 
gum was F6 < F4 < F5 respectively. 
It is evident that the time lag of press coated tablet changes by varying the amount 
of EC and PVP and guar gum in the outer shell. The dissolution profile of F7 & F8 
formulation shows that the release rate is independent of the drug concentration. 
Increase in amount of HPMC in core tablet (formulation F9) increases the lag time. 
The dissolution profile of all the formulated carvedilol time controlled release 
tablets were reported in Table 16. 
CURVE FITTING DATA ANALYSIS: 
The in vitro drug dissolution result of batch F2 was used for in various 
mathematical models (zero, first, Higuchi’s square root and Pappas equation) to 
evaluate the kinetics and mechanism of drug release from the tablets. The model 
that best fits the release data is selected based on the correlation coefficient (r) 
value in various models. The model that gives high ‘r’ value is considered as the 
best fit of the release data. The release constant was calculated from the slope of 
the appropriate plots, and the regression coefficient (r2) was determined (Table 28).  
It was found that the in vitro drug release of optimize batch F2 was best explained 
by zero order model as the plots showed the highest linearity (r2 = 0. 9392), 
Followed by Higuchi’s model (r2 = 0.9252),Korsmeyer–Peppas model (r2 = 
0.8878), and first order (r2 = 0.8826). Drug release was also found to be close to 
zero-order kinetics, indicating that the concentration was nearly independent of 
drug release. The corresponding plot (log cumulative percent drug release vs. log 
time) for the Korsmeyer - Peppas equation indicated a good linearity (r2 = 0.8878). 
The release exponent n was 1.32, which appears to indicate drug release rate was 
independent of time and controlled by a swelling mechanism (case II transport ) it 
mean that follows Zero order drug release mechanism. Drug diffuses at a 
comparatively slower rate as the distance for diffusion increases, which is referred 
to as square root kinetics (or Higuchi’s kinetics). Kinetic models which fit zero 
order and Higuchi are more suitable for controlled release formulations. 
Transverse and longitudinal section view of press coated tablets 
Transverse and longitudinal sections of press coated tablets were made using 
surgical blade in order to verify the position of position of core tablet. Fig.24, 
shows the photographs of these sections. From this, it is clear that core tablet is 
placed in centre of coated tablet. 
STABILITY STUDIES: 
The stability study of the optimized batches in which the tablets were monitored up 
to 3 month at accelerated stability conditions of temperature and relative humidity 
(400 ± 20C, RH 75% ± 5%) (Table No 29). There was little bit but no large 
difference was observed in the evaluation of the optimized batch. The dissolution 
study of the optimized batch at zero month and third month show some changes in 
drug release profile. (Fig. 25) Both the dissolution study show the typical pulsatile 
profile but drug release was somewhat decreas.  
  
SUMMARY AND CONCLUSION 
The main focus of chronotherapeutic formulation of carvedilol is to optimally 
deliver the drug in higher amounts in early morning hours (i.e. at time of greatest 
need) and lower amounts at night (i.e. when the need of drug is less). Because 
systolic blood pressure and diastolic blood pressure rapidly rise in the early 
morning by at least 15 to 25 mm Hg and reach highest levels late in the day. 
Typically SBP and DBP decline in sleep by 10% to 20% from daytime.  
 
From the results it was concluded formulation F2 (EC:PVP, 2:1) and F5 (EC:guar 
gum, 2:1) shows lag time of 5 hours consistent with requirement for 
chronotherapeutics and the drug release was extended as shown in fig.11 and 14. 
The best lag time could be achieved by higher the concentration of EC in outer 
shell. The lag time could also be controlled by altering the weight ratios and 
viscosity grade of polymers. Hence control onset extended press coated carvedilol 
tablets can provide a useful means for timed release and may be helpful for BP 
patients with morning surge, which results in better compliance by patients and 
fewer side effects. 
 
In conclusion, the time lag of press-coated tablet could be modulated by choosing 
the type and amount of excipient used in the outer shell to achieve the time 
controlled disintegration according to the time required The present study indicated 
that the lag time of the press-coated tablet can be suitably modulated by 
formulating the outer shell with ethyl cellulose and PVP or guar gum. 
 
  
REFERENCES 
1. V. S. Chopra Chronotropic Systems; an Emerging Trend in Drug Delivery 
for Pulsed Release in Chronopharmacotherapy International Journal of 
Pharmaceutical and Clinical Research 2010; 2(1): 10-19 
2. Janugade b. U. Formulation and evaluation of press-coated Montelukast 
sodium tablets for pulsatile Drug delivery system International Journal of 
ChemTech Research Vol.1, No.3 , pp 690-691, 
3. Parag A. Kulkarni Development and Evaluation of Press Coated Tablets for 
Chronopharmaceutical Drug Delivery using Gellable and Permeable 
Polymers Scholars Research Library 2010, 2(4): 482-497 
4. Shan-Yang Lin Hydrophilic Excipient Modulate the Time Lag of Time-
Controlled Disintegrating Press-coated Tablets AAPS Pharm Sci Tech 2004  
5. Andrea gazzaniga, oral pulsatile delivery systems – applications and design 
strategies t o uchbriefings 2009 
6. N. Kanaka Durga Devi Chronomodulated drug delivery system of 
Montelukast sodium Scholars Research Library, 2010, 2(5): 316-329 
7. Mayur M. Patel A synchronous colon-specific drug delivery system for 
orally administered mesalamine Acta Pharmaceutica Sciencia 51: 251- 260 
(2009) 
8. Ahmed A Bosela Design of Programmable Release Formulations for 
Combined Therapy Indo-Global Journal of Pharmaceutical Sciences, 2011, 
Vol 1., Issue 2: Page No. 173-185 
9. Sumit Patil Chronomodulated press-coated pulsatile therapeutic system for 
aceclofenac: optimization of factors influencing drug release and lag time 
ChronoPhysiology and Therapy 2011:1 
10. B.G. Prajapati formulation and stastical optimization of time Controlled 
pulsatile release propranolol Hydrochloride compressed coated tablet e -
journal of science & technology 
11. J sajan chronotherapeutics and chronotherapeutic drug Delivery systems 
tropical journal of pharmaceutical research, 2009; 8 (5): 467-475 
12. Richard J. Martin.M.D, Monica Kraft, Chronobiology and 
chronotherapeutics. Eur. J. pharm. Biopharm. 1995; 67: 515-23. 
13. Eiji Fukui, Katsuji Uemura., Studies on applicability of press-coated tablets 
using Hydroxypropylcellulose in the outer shell. J. control.release, 2000; 
68: 215-23 
14. Michael H Smolensky, Nicholas A Peppas., Chronobiology, drug delivery 
and chronotherapeutics. Adv. drug delivery reviews, 2007; 59: 823-24. 
15. Sarasija Suresh, HN Shivakumar., Design and evaluation of pH sensitive 
minitablets for chronotherapeutic delivery of theophylline.,2006;57:456-24 
16. Mukai B., Utoguchi N., Formulation and evaluation of press-coated 
Aminophylline tablet using crystalline cellulose and PEG in the outer shell 
for timed-release dosage forms. Indian j. pharm. Sci., 2002; 78-87. 
17. Martti Marvola, University of Helsinki., Development and 
biopharmaceutical evaluation of press-coated tablets. , 2001; 66-76 
18. Michael Prisant L., Hypertension and chronotherapy shifting the treatment 
paradigm. American j. Hypertension., 2001;14: 277- 79 
19. Hand book of pharmaceutical excipient. sixth edition; Raymond C 
Rowe,Pual J Sheskey and E Quinn page no:129-133,298-300,278-282,346-
349 
20. Polyvinylpyrrolidone Excipients for Pharmaceuticals,1stedition v Buhler 
page no:5-124 
21. Vogel’s Textbook of Quantitative Chemical Analysis, 6th edition, J. 
Mendhan, R. C. Denney, J. D. Bames, M. J. K. Thomas, Page No., 720. 
22. Physical Pharmacy-Physical Chemical Principles in the Pharmaceutical 
Sciences, 4th edition, Martin, P. Bustamante and A. Chun,  Lippincott 
Williams and Wilkins, Baltimore 2002, Page No., 446–448.  
23. Textbook of physical pharmaceutics. 2nd edition, C. V. S. Subramanian, 
Vallabh Prakashan. Delhi. 2000, Page No., 180 - 234  
24. Leon Lachman, Herbert A, Lieberman, Joseph L Kanig: The Theory and 
Practice of Industrial Pharmacy. 3rd ed. India; p: 293-345. 
25. M. Harris shoaib. Evaluation of drug release kinetics from ibuprofen matrix 
tablets using hpmc Pak. J. Pharm. Sci., 2006, Vol. 19(2), 119-124. 
26. Ramon C Hermida, Diana E Ayala., Chronotherapy of hypertension: 
Administration time-dependent effects of treatment on the circadian pattern 
of blood pressure. Adv. Drug delivery reviews, 2007; 59: 923-939. 
27. J. Qureshi, Mohd, Sanjula Baboota., Pulsatile drug delivery systems: An 
approach for controlled drug delivery. Indian j. pharm. Sci., 2006; 68(3): 
295-300. 
28.  D.Searle. LLC., Covera-HS (Verapamil Hcl) Controlled onset extended 
release. Pfizer Publications., March 2006, p: 1-16. 
29. J. Cooper, C. Gunn, Powder flow and compaction In Carter SJ. Tutorial 
pharmacy, New Delhi India, CBS Publishers and Distributors, 1986, 211 
233. 
30. M.E. Aulton, T.I. Wells, Pharmaceutics: The science of dosage form 
Design, London, England, Churchill Livingstone, 1988, 133-135. 
31.  Indian Pharmacopoeia, New Delhi, Ministry of Health and Family Welfare, 
Government of India, Controller of Publications, Vol II, 2007, 662-665. 
32. L. Lachman, H.A. Liberman, J,L. Kanig, The Theory and Practice of 
Industrial Pharmacy, 3rd edition, Mumbai, India, Varghese Publishing 
House, 1999,297-299. 
33. Parag A. Kulkarni. Development and Evaluation of Press Coated Tablets 
for Chronopharmaceutical Drug Delivery using Gellable and Permeable 
Polymers, Der Pharmacia Lettre, 2010, 2(4): 482-497. 
34. Swati C. Jagdale. Design and Evaluation of Enteric Press - Coated Tablet 
for Pulsatile Delivery of Atenolol, International Journal of Pharma world 
ResearchVol-1, Issue 2 - 2010 
35. Abhijit Moon et al. Formulation and evaluation of press -coated 
indomethacin tablets for pulsatile drug delivery system, Journal of 
Pharmacy Research 2011,4(3),564-566. 
36. Janugade BU, Patil SS, Patil SV and Lade PD: Pulsatile drug delivery 
system for chronopharmacological disorders: an overview. Journal of 
pharmacy research 2009; 2(1): 132-143. 
37. Mayur suthar international journal of pharmaceutical research and bio-
science ijprbs, 2012; volume 1(1) 
38. Sarasija S and Pathak S:Chronotherapeutics: emerging role of biorhythms 
in optimizing Drug therapy Indian J Pharm Sci 2005; 67(2): 135-40 
39. Marikki H: Development and biopharmaceutical evaluation of press coated 
tablet taking account of circadian rhythms of disease. Academic 
dissertation, 
40. Sumit Patil Chronomodulated press-coated pulsatile therapeutic system for 
aceclofenac: optimization of factors influencing drug release and lag time 
ChronoPhysiology and Therapy 2011:1 1–10 
41. British Pharmacopoeia 2007.vol I page 390-392 
42. Rang and Dale’s Pharmacology. H.P.Rang, M.M.Dale, J.M. Ritter, 
R.J.Flower. 6th edition. Page no 314-315,179-181,187. 
43. G. yogasanthosh, M. Pharm thesis, Dr M.G.R University, Chennai, 
tamilnadu, India, 2010. 
44. Lemmer B. Chronobiology, drug-delivery, and chronotherapeutics. 
Advance Drug Delivery Review. 2007;59:825–827. 
45. Smolensky MH, Peppas NA. Chronobiology, drug delivery and 
chronotherapeutics. Advance Drug Delivery Review. 2007; 59:828–851. 
46. Rupali Singh, Pramod Kumar Sharma and Rishabha Malviya. Review on 
Chronotherapeutics - A New Remedy in the Treatment of Various Diseases. 
European Journal of Biological Sciences 2 (3): 67-76, 2010 
47. Vogel’s Textbook of Quantitative Chemical Analysis, 6th edition, J. 
Mendhan, R. C. Denney, J. D. Bames, M. J. K. Thomas, Page No., 720. 
48. 1. Evans RM, Marain C. Taking Your Medication: A Question of Timing. 
American Medical Association: 1996:3-8 Evans RM, Marain C, et al, 
editors.eds. Taking Your Medication: A Question of Timing. Chicago, IL: 
American Medical Association; 1996. pp 3-8. 
49. 2. Michael PL. Chronobiology and Chronotherapeutics - Possible Strategy 
for Hypertension and Ischemic Heart Disease [Cited 2009 May 28]. 
Available from: http://www.touchcardiology. com/articles/chronobiology-
and-chronotherape utics-possible-strategy-hypertension-and-ische mic-
heart-diseitishicalournal. 
50. 3. Ura J, Shirachi D, Ferrill M. The chronotherapeutic approach to 
pharmaceutical treatment. California Pharmacist. 1992; 23(9): 46-53. 
51. 4. Subal CB. Chronotherapeutics: Optimising drug delivery [cited 2005 
August 17]. Available from: www.pharmabiz.com/article/detnews. asp? 
Arch=a&articleid= 28993&sectionid=46 
52. 5. Bruguolle B, Lemmer B. Recent advances in chronopharmacokinetics: 
methodological problems. Life Sci 1993; 52: 1809-1824. 
53. 6. Halsas M, Hietala J, Veski P, Jürjenson H, Marvola M. Morning vs. 
Evening dosing of ibuprofen using conventional and time-controlled release 
formulations. Int J Pharm 1999; 189: 179-185. 
54. 7. Halsas M, Ervasti P, Veski P, Jürjenson H, Marvola M. 
Biopharmaceutical evaluation of timecontrolled press-coated tablets 
containing 
55. polymers to adjust drug release. Eur J Drug Metabol Pharmacokinet 1998; 
23: 190-196. 
56. 8. Halsas M, Simelius R, Kiviniemi A, Veski P, Jürjenson H, Marvola M. 
Effect of different combinations of HPMC on bioavailability of ibuprofen 
from press-coated time-controlled tablets. STP Pharma Sci. 1998; 8: 155-
161. 
57. 9. Lamberg L. Chronotherapeutics: implications for drug therapy. American 
Pharmacy 1991; NS31(11): 20-23. 
58. 10. Traynor K, Newton DW, Hrushesky JM, Reiter RJ. A pharmacist’s 
primer on chronotherapeutics. American Pharmacy. 1992; NS32(3): 261-
269. 
59. 11. Homeostasisis. [Cited 2009 May 19]. Available from: http://www.bio-
medicine.org/biologydefinition/ homeostasis/ 
60. 12. Li JJ. Circadian variation in myocardial ischemia: the possible 
mechanisms involving in this phenomenon . Med Hypotheses 2003; 61(2): 
240–243. 
61. 13. Smolensky MH, Labreque G. Chronotherapeutics. Pharm. News1997; 
2: 10-16. 
62. 14. Washington N, Wilson CG. Can oral controlled drug delivery meet the 
challenges posed by chronotherapeutics? [Cited 2009 May 28]. Available 
from: 
63. http://www.egalet.com/multimedia/Chronothera py_May_061.pdf 
64. 15. Lemmer B. Circadian rhythms and drug delivery. J J Contr Release. 
Controlled Release 1991; 16:63-74. 
65. 16. Lemmer B, Bruguolle B. Chronokinetics: are they clinically relevant? 
Clin Pharmacokinet 1994; 26: 419-427. 
66. 17. Lemmer B. and Nold G. Circadian changes in estimated hepatic blood 
flow in healthy subjects. Br J Clin PharmacolBr. J. Clin. Pharma. 1991; 32: 
627-629. 
67. 18. Shiga, Fujimura A, Tateishi T, Ohashi K. And Ebihara A. Differences 
of 
68. chronopharmacokinetic profiles between propranolol and atenolol in 
hypertensive patients. J Clin Pharmacol 1993; 33: 756-761. 
69. 19. Lemmer B, Portaluppi R. Chronopharmacology of cardiovascular 
diseases. In: Redfern PH, Lemmer B. editors. Physiology and 
Pharmacology of Biological Rhythms. Mannheim: Springer-Verlag; 1997. 
p.251-283. 
70. 20. Ollagnier M, Decousus H, Cherrah Y, Levi F, Mechkouri M, Queneau 
P, Reinberg A. Circadian changes in the pharmacokinetics of oral 
ketoprofen. Clin Pharmacokin 1987; 12: 367-378.. 
71. 21. Clench J, Reinberg A, Dziewanowska Z, Ghata, Smolensky M. 
Circadian changes in the bioavailability and effects of indomethacin in 
healthy subjects. Eur J Clin Pharmacol 1981; 20: 359-369. 
72. 22. Guissou P, Cuisinaud G, Llorca G, Lejeune E, Sassard J. 
Chronopharmacokinetic study of a prolonged release form of indomethacin. 
Eur J Clin Pharmacol 1983; 24: 667-670. Sajan et al Trop J Pharm Res, 
October 2009; 8 (5): 4 75 
73. 23. Reinberg A, Levi F, Touitou Y. Clinical pharmacokinetic changes in a 
sustained release preparation of ketoprofen. Annu Rev Chronopharmacol 
1986; 3: 317-320. 
74. 24. Conte U, Colombo P, La Manna A, Gazzaniga A, Sangalli ME, 
Giunchedi P. A new ibuprofen pulsed release oral dosage form. Drug Dev 
Ind Pharm 1989; 15: 2583-2596. 
75. 25. Conte U, Giunchedi P, Maggi L, Sangalli ME, Gazzaniga A, Colombo 
P, La Manna A. Ibuprofen delayed release dosage forms: a proposal for the 
preparation of an in vitro/in vivo pulsatile system. Eur J Pharm Biopharm. 
1992; 38: 209-212. 
76. 26. Conte U, Maggi L, Torre MLP, Giunchedi P and La Manna A. Press- 
coated tablets for timeprogrammed release of drugs. Biomaterials 1993; 14: 
1017-1023. 
77. 27. Vyas SP, Sood A, Venugoplan P. Circadian rhythm and drug delivery 
design. Pharmazie 1997; 52: 815-820. 
78. 28. Bogin RM, Ballard RD. Treatment of nocturnal asthma with pulsed-
release albuterol. Chest 1992; 102: 362-366. 
79. 29. Conte U, Maggi L. Modulation of the dissolution profiles from 
Geomatrix® multi-layer matrix tablets containing drug of different 
solubility. Biomaterials 1996; 17: 889-896. 
80. 30. Ghika J, Gachoud JP, Gasser U. Clinical efficacy and tolerability of a 
new levodopa/benserazide dual-release formulation in parkinsonian 
81. patients. Clin Neuropharmacol 1997; 20: 130- 139. 
82. 31. Ueda S, Hata T, Asakura S, Yamaguchi H, Kotani M, Ueda Y. 
Development of a novel drug release system, time controlled explosion 
system (TES). Part 1. Concept and design. J Drug Target 1994; 2(1): 35-44. 
83. 32. Ueda S, Yamaguchi H, Kotani M. Development of a novel drug release 
system, time controlled explosion system (TES). II. Design of 
multiparticulate TES and in vitro drug release properties. Chem Pharm Bull 
1994; 42: 359- 363. 
84. 33. Narisawa S, Nagata M, Danyoshi C, Yoshino H, Murata K, Hirakawa 
Y, Noda K. An organic acid-induced sigmoidal release system for oral 
85. controlled release preparations. Pharm Res1994; 11: 111-116. 
86. 34. Narisawa S, Nagata M, Ito T, Yoshino H, Hirakawa Y, Noda K. Drug 
release behavior in gastrointestinal tract of beagle dogs from multiple unit 
type rate-controlled or timecontrolled release preparations coated with 
insoluble polymer-based film. J Contr Release J. Controlled Release 1995; 
33: 253-260. 
87. 35. Narisawa S, Nagata M, Hirakawa Y, Kobayashi M, Yoshini H. An 
organic acid-induced sigmoidal release system for oral controlled release 
preparations.2. Permeability enhancement of Eudragit RS coating led by the 
physicochemical interactions with organic acid. J Pharm Sci. 19965; 85: 
184-188. 
88. 36. Gazzaniga A, Sangalli M, Giordano F. Oral Chronotopic® drug 
delivery systems: Achievement of time and/or site specifity. Eur J 
Biopharm 1994; 40: 246-250. 
89. 37. Matsuo M, Nakamura C, Arimori K, Nakano M. Evaluation of 
hydroxyethylcellulose as a hydrophilic swellable material for 
delayedrelease tablets. Chem Pharm Bull 1995; 43: 311-314. 
90. 38. Marvola M, Sirkiä T. Controlled release pharmaceutical preparations. 
Finnish Patent 93924, 26.6.1995. 
91. 39. Sirkiä T, Marvola M, Nikunen S, Tuuri L, Happonen I. 
Biopharmaceutical chracterization of new double-unit controlled-release 
furosemide tablets. Acta Pharm Fenn 1992; 101: 205-214. 
92. 40. Sirkiä T, Mäkimartti, Liukko-Sipi S, Marvola M. Development and 
biopharmaceutical evaluations of a new press-coated prolongedrelease 
salbutamol sulphate tablet in man. Eur J Pharm Sci 1994; 1: 195-201. 
93. 41. Sirkiä T, Niemi J, Marvola M, Lindqvist T, Happonen I. Effect of 
potassium carbonate and viscosity grade of hydroxypropylmethylcellulose 
on bioavailability of furosemide from presscoated prolonged-release tablets. 
STP Pharma Sci 
94. 1994; 4: 257-263. 
95. 42. Sirkiä T, Salonen H, Veski P, Jürjenson H, Marvola M. 
Biopharmaceutical evaluation of new prolonged-release press-coated 
ibuprofen tablets containing sodium alginate to adjust drug release. Int J 
Pharm 1994; 107: 179-187. 
96. 43. Magruder PR, Barclay B, Wong PSL. Composition comprising 
salbutamol. U.S. patent 4,751,071.1988. 
97. 44. Cutler N, Anders R, Stanford S, Sramed J, Awan N, Bultas J, Lahari A, 
Woroszylska M. Placebocontrolled evaluation of three doses of a 
controlled-onset, extended-release formulation of verapamil in the 
treatment of stable angina pectoris. Am J Cardiol 1995; 75: 1102-1106. 
98. 45. Anwar YA, White WB. Chronotherapeutics for cardiovascular disease. 
Drugs 1998; 55: 631- 643. 
99. 46. Hedben J, Wilson C, Spiller R, Gilchrist P, Blackshaw E, Frier M. 
Perkins A. Regional differences in quinine absorption from the undisturbed 
human colon assessed using a timed release delivery system. Pharm Res 
1999; 16: 1087-1092. 
